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 Skin cancers including non-melanoma skin cancer (NMSC) and melanoma are the most 
common form of cancer in the United States and thus represent a substantial burden to the health 
care system. Current chemotherapeutic treatments for skin cancer cause harmful side effects due 
to lack of tumor-cell selectivity. Our group previously found that the endocannabinoid, 
arachidonoyl-ethanolamide (AEA), induces apoptosis in tumor but not non-tumor cell lines 
through its metabolism to novel J-series prostaglandin-ethanolamides (prostamides). Therefore, 
the goal of this study was to synthesize the novel prostamide, 15-deoxy-Δ12,14-prostamide J2 (15d-
PMJ2) and determine the molecular mechanism of its antineoplastic activity. To our knowledge, 
we are the first group to successfully synthesize and biologically characterize a J-series 
prostamide. 15d-PMJ2 exhibited potent and selective apoptotic properties in both non-melanoma 
and melanoma skin cancers. Furthermore, 15d-PMJ2 was a potent inducer of tumor cell apoptosis 
in vivo. Induction of endoplasmic reticulum (ER) stress was required for 15d-PMJ2 –mediated 
 
 
cancer cell death and was an important determinant of selective toxicity. This project also 
conducted a targeted structure-activity assessment of the electrophilic double bond, definitively 
showing this moiety as the molecular “warhead” necessary for the cytotoxic activity. Taken 
together, these data provide sound evidence that 15d-PMJ2 may provide a clinical alternative for 
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CHAPTER ONE: GENERAL INTRODUCTION 
 
1.1 Cancer  
Cancer is the second leading cause of death in the United States and is characterized by the 
uncontrolled proliferation of malignant cells [1]. These autonomously expanding cells invade 
nearby tissues, promote angiogenesis and migrate throughout the body (metastasis). The process 
of tumor formation is known as carcinogenesis and consists of three distinct phases. Initiation 
occurs when a carcinogen causes irreversible DNA alterations within oncogenes or tumor 
suppressor genes of a cell. Oncogenes encode proteins that promote cell proliferation, growth, and 
cell cycle progression while tumor suppressor genes typically regulate cell death and cell cycle 
arrest. The subsequent phase of carcinogenesis is known as promotion, which occurs when an 
initiated cell undergoes clonal expansion and is amplified into a benign tumor. Finally, progression 
is the last phase of carcinogenesis and results in autonomous and unregulated malignant cell 
growth. While cancerous cells can develop from any tissue type within the body, some cancers 
occur more frequently than others.      
1.1.1 Non-Melanoma Skin Cancer  
Non-melanoma skin cancer (NMSC) is the most frequently diagnosed cancer in the United 
States with over 5 million new lesions diagnosed annually [2]. The direct cost of NMSC treatment 
was estimated to be 4.8 billion dollars, representing a significant financial cost to the United States 
health care system [3]. Basal cell carcinoma (BCC) is the most common form of NMSC and arises 
from basal layer cells of the epidermis. The majority of BCCs occur due to exposure to natural and 
artificial sources of ultraviolet (UV) light and are commonly found on sun-exposed areas of 
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the body including the face, ears, neck, and the backs of the hands [4]. Squamous cell carcinoma 
(SCC) on the other hand, is the second most common form of NMSC, originating from squamous 
layer keratinocytes of the epidermis [4]. Like BCC, exposure to UV light is the most common 
cause of SCC, however, exposure to chemical carcinogens such as arsenic and polycyclic-aromatic 
hydrocarbons also contribute to SCC incidence. Other risk factors for developing these skin 
cancers include poor immune function or rare genetic defects (such as in xeroderma 
pigmentosum). Typical treatments for NMSC include surgical removal and topical therapy with 
5-fluorouracil (5-FU) or imiquimod [5]. While the mortality rate for NMSC is low, the high 
recurrence rate and detrimental side effects associated with current topical treatments indicate the 
need for novel NMSC chemotherapeutic agents.  
1.1.2 Melanoma Skin Cancer    
 Melanoma is the most aggressive and deadly form of skin cancer in the United States. It is 
estimated that more than 76,000 new cases of melanoma will be diagnosed and that over 10,000 
of these individuals will succumb to the disease each year [6]. Like NMSC, UV radiation exposure 
is a primary risk factor for developing melanoma, and individuals with family history, poor 
immune function or xeroderma pigmentosum may also be at increased risk of developing this 
malignancy [7]. Unlike other forms of skin cancer, melanoma is especially dangerous due to its 
highly metastatic nature and resistance to chemotherapy. Melanoma is known to progress in three 
distinct stages: the radial stage in which melanoma cell proliferation occurs locally within the 
epidermis, the vertical stage in which melanoma cells invades the dermis layer, and the metastatic 
stage which occurs when melanoma cells disseminate into peripheral tissues. Treatment of 
melanoma skin cancer includes surgical excision followed by chemotherapy and radiation therapy. 
Melanoma is resistant to most chemotherapeutic agents, however, positive clinical outcomes have 
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been observed with immunotherapeutics and small molecule inhibitors of the MAPK pathway. 
Immunotherapeutic agents such as the checkpoint inhibitors block cytotoxic T-lymphocyte-
associated protein 4 (CTLA4) thereby triggering immune-mediated tumor cell destruction. Several 
studies report that checkpoint inhibitors increase patient survival rates [8]. In addition, the mitogen 
activated protein kinase (MAPK) pathway is an important driver for melanoma proliferation and 
includes several important targets including BRAF and ERK [9]. Downstream signaling of the 
MAPK pathway has been demonstrated to be hyperactive in up to 90% of human melanoma cases 
[9]. Thus, treatments with BRAF inhibitors including vemurafenib and dabrafenib significantly 
decrease tumor growth and are currently being utilized clinically [9]. Recently, melanomas found 
to possess aberrant signaling of this MAPK pathway have been demonstrated to persistently 
express heightened levels of pro-survival endoplasmic reticulum stress activation [10;11]. This 
suggests that agents which propagate endoplasmic reticulum stress may provide a novel 
therapeutic approach to combating BRAF overexpressing melanoma skin cancer.  
1.1.3 Mouse Models for Skin Cancer  
Mouse tumor models have become a mainstay for preclinical cancer research due to their 
ability to produce predictable tumor growth while in specific models maintaining the tumor 
microenvironment. The most common model used to study NMSC development is the two-staged 
chemical carcinogenesis model. This model employs two carcinogens (e.g. DMBA and TPA) or 
one complete carcinogen (e.g. UVB-light) that have the ability to initiate and promote 
tumorigenesis. For NMSC, DMBA is topically applied as an initiator followed by subsequent 
repeated doses of TPA used as a promoter. The two-staged chemical carcinogenesis model is 
particularly useful for testing the preventative and therapeutic properties of antineoplastic. The 
drawbacks of this model is that tumors are of murine origin and tumor formation can take upwards 
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of six months. Distinct from NMSC, implantable or grafted tumor models are the most commonly 
used method to examine melanoma skin cancer. The two major subtypes of these models are the 
syngeneic (allograft model), in which tumor cell lines of host origin are subcutaneously injected 
into immune-competent animal and the xenograft model, where cells distinct from the implantation 
host are subcutaneously injected or grafted into immune-deficient mice [12]. Allograft models 
provide the advantage of evaluating the immunogenic effects of anti-cancer agents while xenograft 
models provide an opportunity to evaluate efficacy of anti-cancer agents on a patient-derived 
tumor [12]. The advantage of the classic B16F10 model include the rapid time period of tumor 
growth (1 to 2 weeks) and the ability to monitor immunogenic endpoints. In this dissertation, 
B16F10 melanoma cells will be subcutaneously inoculated into the flank region of C57BL/6 mice 
[12].   
1.2 The Role of Prostaglandins in Cancer  
 Cyclooxygenase-2 (COX-2) is a 73 kDa protein which is overexpressed in many cancers 
including NMSC and melanoma [13-15]. COX-2 converts arachidonic acid, a long chain 
polyunsaturated fatty acid, to prostaglandin G2 and then to prostaglandin H2 (PGH2) [16;17]. PGH2 
then serves as a substrate for a variety of prostaglandin isomerases including prostaglandin E 
synthase (PGES), prostaglandin F synthase (PGFS) and prostaglandin D synthase (PGDS) which 
metabolize PGH2 to PGE2, PGF2α, and PGD2, respectively [18]. Non-enzymatic dehydration of 
prostaglandin D yields the pro-apoptotic J-series prostaglandins [19]. 
1.2.1 E-series Prostaglandins in Cancer  
 The upregulation of COX-2 in many types of epithelial tumors is accompanied by a high 
level of prostaglandin synthesis. Most notably, prostaglandin E2 (PGE2) has been shown to be 
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important for tumor development in many cell types including skin cancer, colorectal cancer and 
breast cancer [13;20]. PGE2 elicits its activity by binding to four distinct G-protein coupled 
receptors referred to as EP1, EP2, EP3, and EP4 [21]. EP1 receptor activation increases intracellular 
calcium and protein kinase C (PKC) activation while EP2 and EP4 signaling results in increased 
cyclic AMP and activation of protein kinase A (PKA) [21]. Downstream of the EP receptor, a 
variety of signal transduction proteins are stimulated that are associated with tumorigenesis 
including AKT (cell survival), VEGF receptor transactivation (angiogenesis), NF-κB/COX-2 
(inflammation) and Cyclin D1 (cell proliferation) [20]. Thus, COX-2 mediated production of E-
series prostaglandins is a key driver of tumor proliferation in COX-2 overexpressing cancers such 
as colorectal, NMSC, and melanoma.   
1.2.2 D-series prostaglandins  
Similar to other prostaglandin subtypes, the physiological effects of the D-series 
prostaglandins are mediated through cell surface receptors. DP1 receptors are G-s protein coupled 
receptors found mostly in epithelial cells and eosinophils while DP2 receptors are G-i protein 
coupled receptors found in eosinophils and Th2-type lymphocytes [22;23]. DP receptor activation 
modulates numerous immune responses including eosinophil activation and Th2 mediated 
cytokine production [24;25]. In cancer, some groups reported that DP1 and DP2 receptor 
upregulation is associated with tumor invasion and metastasis, while others showed that DP 
receptor signaling exerts a suppressive effect on tumor growth [26]. These discrepancies may be 
due to the fact that PGD2 is non-enzymatically dehydrated to J-series prostaglandins including 
PGJ2, Δ
12-PGJ2, and 15-deoxy-Δ
12,14-PGJ2 [27;28]. Because it is currently not possible to block 
the conversion of D-series prostaglandins to J-series prostaglandins, the role of PGD2-mediated 
DP receptor signaling on tumor development remains unclear [29]. 
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1.2.3 The Cytotoxic Effects of J-series Prostaglandins    
 J-series prostaglandins such as prostaglandin J2 (PGJ2), Δ
12-prostaglandin J2 and 15-deoxy-
Δ12,14-prostaglandin J2 (15d-PGJ2) are naturally occurring derivatives of prostaglandin D2  [27]. It 
has been reported by our group and numerous others that J-series prostaglandins are potent 
inducers of tumor cell apoptosis [30-33]. Additionally, some groups have reported that 15d-PGJ2 
markedly reduces tumor cell growth and causes tumor cell apoptosis in vivo [33;34]. Unlike other 
classes of eicosanoids, these chemically distinct lipids possess an electrophilic α,β-unsaturated 
carbonyl group on the cyclopentenone ring which can readily react by Michael addition with free 
sulfhydryls of cellular proteins [27;35;36]. This reactive cyclopentenone ring is suggested to cause 
tumor cell apoptosis and initiate a variety of biological effects including the generation of 
endoplasmic reticulum stress and oxidative stress [37;38] 
1.2.4 Ethanolamide Conjugated Prostaglandins (Prostamides) 
COX-2 has been implicated in metabolizing endogenous cannabinoids (endocannabinoids) 
to prostaglandins [39]. Specifically, arachidonyl ethanolamide (AEA), is converted to prostamide 
H2 (PMH2) by COX-2 and upon subsequent reaction with prostaglandin synthases, ethanolamide-
conjugated prostaglandins (prostamides [PMs]) are produced (Figure 1.1) [40-42]. As such, COX-
2 mediated metabolism of AEA leads to production of prostamide D2 (PMD2), prostamide E2 
(PME2), and prostamide F2α (PMF2α). Our laboratory demonstrated by mass spectral analysis that 
conversion of PMH2 to PMD2 by prostaglandin D synthase PGDS results in the formation of 
prostamide J2, Δ
12 prostamide J2, and the terminal cytotoxic product, 15-deoxy- Δ
12,14 -prostamide 
J2 (15d-PMJ2) (Figure 1.1) [43]. Although structurally similar to arachidonic acid-derived 
prostaglandins, prostamides possess unique pharmacology and biological activity compared to 
their non-ethanolamide counterparts [44]. This is due to the fact that prostamides do not bind to 
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traditional prostaglandin receptors and many groups have suggested the existence of distinct 
prostamide receptors [44;45]. In most cases the biological activity of prostamides has yet to be 




























Figure 1.1: COX-2-mediated metabolism of arachidonoyl-ethanolamide to prostamides 
Arachidonoyl-ethanolamide is converted to prostamide H2 by COX-2 followed subsequent 
metabolism by prostaglandin F synthase (PGFS), prostaglandin D synthase (PGDS) and 
prostaglandin E synthase (PGES) to prostamide F2α, prostamide D2, and prostamide E2, 
respectively. Prostamide D2 then undergoes spontaneous dehydration and isomerization to 
prostamide J2, Δ
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1.3 Endoplasmic Reticulum Stress 
Endoplasmic reticulum (ER)-stress occurs when normal protein folding efficiency is 
compromised, causing a buildup of unfolded proteins and eliciting what is known as the unfolded 
protein response (UPR) [46;47]. Eukaryotic cells are equipped with specific stress response 
pathways, designed to recognize the accumulation of misfolded or unfolded proteins in order to 
restore homeostasis. The presence of unfolded proteins in the ER increases the recruitment of 
protein folding chaperones, including HSP70/GRP78 (BiP) to the nascent, unfolded peptides. 
Sequestration of BiP results in the liberation of the three ER-localized UPR sensors, PERK, ATF6, 
and IRE1 to propagate their signals [48]. Homodimerization and auto-phosphorylation of RNA-
dependent protein kinase (PKR)-like ER kinase (PERK) attenuates general protein synthesis. 
PERK mediated phosphorylation of the eukaryotic translation initiation factor, eiF2α, results in 
selective translation of activated transcription factor 4 (ATF4) [47]. On the other hand, dissociation 
of BiP from activated transcription factor 6 (ATF6) leads to its translocation to the Golgi-apparatus 
where it is cleaved to its active form [49]. In the third arm of the ER-stress pathway, IRE1 is 
activated by autophosphorylation and homodimerization, and then catalyzes the splicing of X-box 
binding protein 1 (XBP1) mRNA. The XBP-1 protein product then binds to promoters of several 
genes involved in restoring protein homeostasis [48]. Two known ER-stress inducing agents are 
thapsigargin and tunicamycin which exert their effects by inhibiting Ca2+ channels and blocking 
N-linked glycosylation, respectively.  
Depending on intensity and duration of the ER-stress signal, tumor cells can undergo either 
pro-survival or pro-apoptotic signaling. In the survival pathway, IRE1, ATF4 and ATF6 induce 
expression of proteins involved in peptide folding, anti-oxidant responses and protein degradation 




pathway, these sensors upregulate the expression of transcriptional factor C/EBP homologous 
protein (CHOP10)/growth arrest and DNA damage inducible 153 (GADD153), thereby triggering 
apoptosis through direct inhibition of Bcl-2 transcription, activation of death receptors (DR5) and 
induction of endoplasmic reticulum oxioreductase-1 (ERO1α)  [46-49] ).  
1.3.1 The Role of CDIP1 in ER-stress  
Cell death inducer p53 target 1 (CDIP1) is a 21 kDa protein which is found to be 
upregulated during DNA damage and acts as a p53-mediated apoptotic initiator. Moreover, CDIP1 
was recently found to be a key regulator of ER-stress mediated apoptosis, with knockdown of 
CDIP1 preventing ER-stress-apoptosis mediated by tunicamycin and thapsigargin in vitro and in 
vivo [50]. During ER-stress, CDIP1 translocates to the ER and complexes with B-cell receptor 
associated protein 31 (BAP31) resulting in the formation of a CDIP1-BAP31 complex [50]. This 
CDIP1-BAP31 complex triggers the cleavage of BAP31 by caspase-8 into the p20-BAP31 
fragment, possesses pro-apoptotic function. The complexation of CDIP1 and BAP31 causes 
oligomerization of BAX proteins, a member of the BH3 protein group which migrate to the ER 
and mitochondrial membranes. These BAX proteins then undergo conformational changes, 
resulting in the formation of homodimeric clusters and the formation of oligomeric pores leading 
to release of apoptotic factors including cytochrome c [51]. The complexation between CDIP1 and 
BAP31 was found to be required for BAX oligomerization and genetic knockdown of CDIP 
completely abrogated this effect [50]. Collectively, these findings suggest that CDIP1 plays an 
important in regulating the crosstalk between the ER and mitochondria during ER-stress mediated 





1.3.2 Regulation of ER calcium homeostasis during ER-stress 
 The ER serves as a major Ca2+ storage and buffering organelle, providing an ideal 
environment for Ca2+ handling, protein-folding chaperones [52]. The ER achieves large luminal 
Ca2+ concentrations compared to the cytosol by operating the transmembrane ER calcium pump 
known as the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA). Once inside the ER, Ca2+ can 
be stored and ultimately utilized by binding to ER-resident chaperone proteins including BiP 
(GRP78), calreticulin (CRT), calnexin (CNX), and protein disulfide isomerase (PDI) [53]. Outflow 
of Ca2+ from the ER is primarily mediated by the ryanodine (RyR) and inositol 1,4,5-triphosphate 
receptors (IP3R). As such, significant fluctuations in ER Ca
2+ levels have been shown to be the 
cause and consequence of ER-stress induction. Indeed, the ER-stress inducing agent thapsigargin 
exerts its activity by interrupting SERCA mediated Ca2+ uptake, which is crucial for protein folding 
[54]. Regulation of Ca2+ trafficking during ER-stress is considered biphasic in nature, where low 
levels of unfolded protein result in endoplasmic reticulum protein-44 (ERp44)-mediated protection 
of Ca2+ store depletion, whereas, bouts of prolonged UPR and ER-stress, lead to PERK and 
BAP31-mediated induction of IP3R-mediated bolus Ca
2+ release [55;56].   
1.3.3 Mitochondria/ER calcium signaling during cell death 
 Similar to the ER, the presence of Ca2+ within the mitochondria aids in critical organelle 
functions. Mitochondrial Ca2+ levels play a vital role in bioenergetic processes including ATP 
synthesis. Mitochondrial Ca2+ is pumped from the cytosol into the outer mitochondrial membrane 
through the voltage-dependent anion-selective channel (VDAC) and subsequently into the 
mitochondrial lumen through the mitochondrial calcium uniporter (MCU). The Ca2+ flux between 
the ER and mitochondria occur at locations recognized as mitochondrial-associated ER 




mitochondrial VDACs [57]. Indeed, the ebb and flow of Ca2+ between these organelles plays a 
homeostatic role in the maintenance of metabolic and protein folding functions. Conversely, 
perturbations in Ca2+ signaling can become propagated during altered ER protein folding and redox 
status [56]. Specifically, ER-stress causes sustained IP3 receptor mediated mitochondrial Ca
2+ 
uptake, known to activate the intrinsic apoptotic pathway by opening the mitochondrial 
permeability transition pore (mPTP) [57;58]. The resulting effect is the release of cytochrome c, a 
factor which activates the executioner caspase cascade, causing apoptotic cell death.    
1.3.4 ER-stress Induction as a Chemotherapeutic Avenue 
Studies have revealed that agents capable of targeting ER-stress can selectively inhibit 
proliferation or cause tumor cell apoptosis. Agents with tumor cell selective characteristics are 
preferred as they are associated with fewer adverse effects. It is well established that basal levels 
of ER-stress are heightened in cancer cells as a result of the increased protein demand during 
uncontrolled cell proliferation [49]. In addition, hypoxic conditions within most tumors impairs 
ATP production and leads to the accumulation of unfolded proteins [49] In contrast, ER-stress is 
typically inactive in normal cells. These observations provide a basis for selective toxicity, the 
ability to target tumor cells, while causing limited harm to normal cells, thus minimizing side-
effects. As such, antineoplastic agents are currently being utilized to modulate the ER-stress 
pathway as a therapeutic target [59]. Clinically available agents that target the UPR include 
irestatin, which inhibits the UPR sensor IRE1α, thereby inhibiting cell proliferation and 
bortezomib, which exacerbates ER-stress mediated death by blocking proteasome activity [60]. 
Furthermore, non-melanoma and melanoma skin cancers have demonstrated susceptibility to these 





CHAPTER TWO: MATERIALS AND METHODS 
2.1 Antibodies and Reagents 
 15-deoxy, Δ12,14-prostaglandin J2 and 9,10-dihydro-prostaglandin J2 were purchased from 
Cayman Chemical company (Ann Arbor, MI). TBTU, ethanolamine, diispropylethylamine, 
acetonitrile (ACN), deuterated chloroform (CDCl3), and the antibody for β-actin were purchased 
from Sigma-Aldrich (St. Louis, MO). Antibodies directed toward full length/cleaved caspase-3, 
full length/cleaved PARP, full length/cleaved caspase-8, full length caspase 4, P-PERK and total-
PERK were from Cell Signaling Technologies (Beverley, MA). Cleaved caspase-4 was from 
Invitrogen (Grand Island, NY), Anti-CHOP10 and anti-BAP31 antibodies were from Santa Cruz 
Biotechnology (Santa Cruz, CA), anti-GAPDH was from Millipore (Billerica, MA) and anti-
CDIP1 was from Novus Biologicals (Littleton, CO). Anti-rabbit 800CW and anti-mouse 680RD 
secondary antibody IRDyes were from Li-cor Biosciences (Lincoln, NE). Anti-rabbit Alexafluor 
555 was from Invitrogen (Grand Island, NY) while anti-rat Alexafluor was from Jackson 
Immunoresearch (West Grove, PA). Caspase-Glo® 3/7 assays and MTS reagent were from 
Promega Life Sciences (Madison, WI).  
2.2 Synthesis of Novel Prostamides (Chapter 3) 
 15-deoxy-Δ12,14-prostaglandin J2 or 9,10-dihydro-prostaglandin J2 (Cayman Chemical, 
Ann Arbor, MI.) was dissolved in a small volume (10mL) of acetonitrile, approximately 1.5 
mole equivalent of O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate 
(TBTU), and 2 mole equivalents of diisopropylethylamine were added. The solution was stirred 
for approximately 60 minutes and 2 mole equivalents of ethanolamine were added. The reaction 




crude product. This product was re-dissolved into 1:1 ACN:H2O and purified by HPLC 
(spectroscopic yield 99%), which was characterized by 1H NMR (400MHz, CDCl3): 0.921 (t, 
3H); 1.340 (m, 4H); 1.482 (m, 2H); 1.706 (q, 2H); 2.053 (q, 3H); 2.177 (t, 2H); 2.258 (q, 2H); 
2.372 (m, 1H); 2.592 (m, 1H); 3.439 (q, 2H); 3.634 (m, 1H); 3.744 (t, 2H); 5.365 (m, 1H); 5.472 
(m, 1H); 5.953 (s, 1H); 6.311 (m, 3H); 6.965 (d, 1H); 7.510 (m, 1H); and ESI-MS: [M+H]+ 
360.2270. Patent # 9,328,060. 
2.3 Cell Lines and Cell Culture 
 Non-tumorigenic HaCaT keratinocytes (purchased from Cell Line Service, Eppelheim, 
Germany), human squamous carcinoma cell line A431 (purchased from ATCC, Manassas, VA)  
and mouse B16F10 melanoma cells (a kind gift from Dr. Li Yang, East Carolina University) were 
cultured in Dulbecco’s Modified Eagle Medium (Invitrogen, Carlsbad, CA) containing 10% heat 
inactivated fetal bovine serum (FBS), penicillin (100 mg/mL), streptomycin (100mg/mL), sodium 
pyruvate, and glutamine. The murine melanocyte Melan-A cell line was purchased from the 
Bennett-Sviderskaya laboratory (Molecular Cell Sciences Research Centre, St. George’s, 
University of London, UK) and cultured in Roswell Park Memorial Institute (RPMI)-1630 medium 
supplemented with 10% fetal calf serum, penicillin (100mg/mL), streptomycin (100mg/mL), 
glutamine  and tetradecanoylphorbol acetate (200 nM). Patient melanoma tissue (acquired from 
Dr. Timothy Fitzgerald ECU, Dept. of Surgery) was washed and dissociated using collagenase 
type 4 (Worthington Biochemical Corporation, Lakewood, NJ) then cultured in Mel 2% medium 
containing MCDB 153/Leibovitz L-15 medium (80%/20%), 2% heat inactivated FBS, insulin 
(5µg/mL), calcium chloride (1.68mM) and bovine pituitary extract (15 µg/mL). The identity of 
the primary melanoma cells were verified by measuring tyrosinase levels via confocal microscopy. 




Medium (US Biological, Swampscott, MS) containing 5% heat inactivated FBS, penicillin (100 
mg/mL), streptomycin (100 mg/mL), nonessential amino acids and glutamine. JWF2 cells were a 
kind gift from Dr. Susan Fischer (University of Texas, MD Anderson Cancer Center, Smithville, 
TX). 
2.4 Cell Viability Assays 
 A431, HaCaT, B16F10, Melan-A, JWF2 or primary melanoma cells were plated in 96-well 
dishes and cultured for 48hrs. Serum-free medium containing different concentrations of 15d-
PMJ2, 15d-PGJ2 or other agents were then added to the cells. Twenty microliters of MTS reagent 
were added to each well after 12-24 hours of incubation and absorbance was measured at 495nm 
as directed by the manufacturer (Promega, Madison, WI). LC50 (concentration required to kill 50% 
of the cell population) values were determined using GraphPad software.  
2.5 Caspase-3/7 Activity Assay 
Cells were plated in white-walled 96-well plates and cultured for 48 hours. Medium 
containing the appropriate agents were added to the cells for the indicated amount of time. One 
hundred microliters of Caspase-Glo 3/7 reagent was then added to each well as directed by the 
manufacturer and luminescence was measured using a Tecan luminometer.  
2.6 E- and J-series Prostaglandin ELISA Assay  
 Culture medium collected from JWF2 and HaCaT cells was assayed for E- and J-series 
prostaglandins using ELISA kits according to the manufactures’ use protocol as described 
previously [43]. 




 All cell lines were incubated in medium containing the indicated agents. Plates were 
subsequently scraped and protein concentration of the cell lysates was determined with BCA 
reagents (Pierce, Rockford, IL). Equal concentrations of each sample were loaded onto SDS-
PAGE gels and protein bands transferred to nitrocellulose membranes (GE Healthcare Life 
Sciences, Piscataway, NJ). Blocked membranes were incubated with Peirce Protein Free Blocking 
Buffer (Thermo Scientific, Waltham, MA) containing full length (FL)/cleaved caspase-3 (1:1000), 
full length (FL)/cleaved caspase-4 (1:1000), full length (FL)/cleaved caspase-8 (1:1000)  
FL/cleaved PARP (1:1000), anti-P-PERK (1:500), anti-t-PERK (1:500), anti-CHOP10 (1:1000), 
anti-β-actin (1:5000), anti-GAPDH (1:5000), or anti-CDIP1 (1:1000) antibodies. Protein bands 
were visualized using the Li-cor system (Lincoln, NE) and digitized images were quantified using 
ImageJ software (https://imagej.nih.gov/ij).    
2.8 Oxidative stress measurement 
 The oxidative stress in JWF2 and B16F10 cells was measured using the probe 
chloromethyl-2,7 dichlorodihydrofluorescein diacetate (CM-H2DCFDA, Molecular Probes, 
Invitrogen). Cells were treated with appropriate drugs using phenol red-free, serum-free medium 
for the indicated time followed by incubation with PBS solution supplemented with magnesium 
and calcium containing CM-H2DCFDA. Cells were then dissociated from the culture dish using 
Hank’s Enzyme free dissociation buffer and re-suspended in phenol red-free serum-containing 
media. Mean fluorescence was measured using an Accuri C6 flow cytometer (BD Accuri 
Cytometers, Ann Arbor, MI, USA) at an excitation wavelength of 488nm and an emission filter of 
533 ± 33nm.   




 To measure intracellular [Ca2+], treated cells were incubated with Fluo-4-NW at 37ºC for 
30 minutes in HBSS (without Mg2+ or Ca2+). Mean fluorescence was measured using a Tecan 
Infinite Pro M200 plate reader (Mannedorf, Switzerland) at an excitation wavelength of 493 nm 
and an emission filter of 513 ± 33nm.   
2.10 Mitochondrial [Ca2+] measurements 
 To measure mitochondrial [Ca2+] levels, treated cells were incubated with Rhod-2 (1mM) 
at 37ºC for 30 minutes in PBS (without Mg2+ or Ca2+). Mean fluorescence was measured using an 
Accuri C6 flow cytometer (BD Accuri Cytometers, Ann Arbor, MI, USA) at an excitation 
wavelength of 533 nm and an emission filter of 614 ± 33nm.   
2.11 Immunocytochemistry 
 A431 cells were grown on culture slides followed by incubation in medium containing the 
indicated agents. Cells were then fixed with methanol, incubated with permeabilization buffer 
(0.1% Triton X-100 in PBS) for 10 minutes, and blocked with blocking buffer (PBS + 3% FBS + 
0.5% Tween20) for 1 hour. Blocked cells were then incubated with indicated primary antibodies 
and the appropriate immunofluorescence-tagged secondary antibodies. Images were acquired and 
analyzed by confocal laser microscopy (Zeiss LSM 700 confocal microscope system). 
Fluorescence intensity was quantified using Zen Blue software.   
2.12 B16F10 Allograft Studies 
 All experiments were approved and conducted in accordance with East Carolina University 
IACUC guidelines. C57BL/6 female mice (7-week old animals) were purchased from Jackson 
Laboratories (Bar Harbor, ME). The flank region was shaved and tumors established by 




became palpable (7 - 10 days post implantation), mice were either given daily peritumor injections 
(0.5 mg/kg 15d-PMJ2 or PBS as vehicle) or left untreated as a control for 5 days. Animal body 
weights were measured and recorded daily. The length and width of the tumors were measured 
daily with calipers (daily tumor volume was calculated as: Volume = Length2 x Width x (π/6)). 
After mouse euthanasia, tumors were dissected, blotted dry and weighed at the end of the study.  
2.13 Immunohistochemistry 
Tumors and livers were formalin-fixed, paraffin-embedded and sectioned at 5µm 
thickness. Sections were deparaffinized and rehydrated with a series of ethanol solutions and 
water. Endogenous peroxidase activity was blocked with 3.0% hydrogen peroxide for 30 minutes 
at room temperature. Sections were then incubated overnight with primary antibody followed by 
secondary antibody for 30 minutes. Preliminary experiments were conducted to optimize 
conditions for primary and secondary antibody. Staining was visualized using the Superpicture 3rd 
GEN IHC Detection Kit (ThermoFisher, Waltham, MA) then counterstained in Harris’ 
hematoxylin. Terminal deoxynucleotidyl transferase deoxyuridine triphosphate nick-end labeling 
(TUNEL) staining of paraffin-embedded tumor and liver sections was performed according to 
standard protocols provided by the manufacturer (Roche Diagnostics, Mannheim Germany). Four 
fields were evaluated per section with a minimum of twelve sections examined per tumor.  
2.14 Statistical Analysis 
Data are representative of three independent experiments unless otherwise indicated. Data 
are presented as mean ± standard error of the mean (SEM). Student’s t-test, one- and two-way 





CHAPTER THREE: SYNTHESIS AND VERIFICATION OF NOVEL J-SERIES 
PROSTAMIDES 
3.1 ABSTRACT 
Our previous data showed that AEA-induced apoptosis in a COX-2-dependent manner. 
Subsequent findings also showed that AEA was metabolized by COX-2 and mass spectral analysis 
demonstrated that the novel prostamide, 15-deoxy-∆12,14 prostamide J2 (15d-PMJ2) was a primary 
metabolic product. As such, this study sought to synthesize 15d-PMJ2 to determine if the cytotoxic 
activity of AEA was mediated by this J-series metabolic product. 15d-PMJ2 was synthesized by 
using a coupling reagent in the presence of N,N-diisoproylethylamine (DIEA) and ethanolamine. 
The uronium salt TBTU was chosen as the most appropriate coupling reagent as HBTU possessed 
limited solubility while removal of byproducts of carbodiimides such as DIC poses a difficulty. 
The model compound linoleoyl-ethanolamide was synthesized and verified by 1H-NMR following 
liquid/liquid extraction work-up with diethyl-ether. Recovery and yield were reported to be 88% 
and 95% respectively. To determine the effect on lipids containing double bonds, the model 
compound AEA was synthesized from arachidonic acid and verified by 1H-NMR and ESI-MS. 
Recovery and yield were found to be comparable to linoleoyl-ethanolamide. The cytotoxicity of 
synthetic AEA in COX-2 overexpressing tumorigenic keratinocytes was found to be by 43% at 20 
µM and 92% at 30 µM, respectively. The cytotoxicity of synthesized AEA was found to be similar 
but slightly higher than commercially available AEA. Finally, 15d-PMJ2 was synthesized from 
15d-PGJ2 in the presence of TBTU and ethanolamine. High performance liquid chromatography 
was chosen to purify 15d-PMJ2, thereby significantly increasing recovery. The identity, purity and 
reaction yield of 15d-PMJ2 was verified by 





3.1 INTRODUCTION  
 Our laboratory previously established that AEA potently and selectively induced apoptotic 
cell death in COX-2 overexpressing tumorigenic keratinocytes [31]. Furthermore, mass spectral 
analysis indicated the presence of a novel J-series prostamide as a primary COX-2 metabolite. 
Thus, we hypothesized that the cytotoxic activity of AEA was mediated by this J-series 
prostamide. To investigate the anti-tumor activity of 15d-PMJ2, an approach was developed to 
synthesize 15d-PMJ2, as this molecule is not commercially available. Specifically, this approach 
involved the attachment of an ethanolamine group via formation of an amide bond by using a 
coupling reagent and reacting the commercially available carboxylic acid containing J-series 
prostaglandin (15-deoxy Δ12,14 prostaglandin J2) with ethanolamine to form the J-series 
prostaglandin-ethanolamide (prostamide) product. The collective strategy for optimizing yield and 
recovery was to first begin by producing ethanolamide conjugates using inexpensive and readily 
available saturated fatty acid compounds then transitioning to polyunsaturated fatty acids and 
finally to the J-series prostaglandin (figure 3.1).   
 The amide moiety is a common feature found in many classes of natural molecules, 
including proteins, lipids, and carbohydrates. In nature, the process of amide bond formation is 
very complex and requires specialized coordination of many macromolecules including enzymes, 
ribosomes, mRNAs, and tRNAs. In lipids and endocannabinoids such as AEA, the amide-
ethanolamine group is produced in a two-step process. First, the arachidonic acid component is 
transferred from arachidonoyl-phosphatidylcholine (PC) to phosphatidylethanolamine (PE) by N-
acyltransferase (NAT). Next, N-arachidonoyl-phosphatidylethanolamine (NAPE) is cleaved by 




of arachidonic acid from the ethanolamide group is carried out by fatty acid amide hydrolase 
(FAAH).  
 In the laboratory setting, amide bond formation is carried out by a coupling reaction which 
typically involves the following steps: activation of a carboxylic acid, attachment of a leaving 
group to the acyl carbon of the acid, and attack of the amino group. In general, a multitude of 
different strategies using different coupling reagents has been developed aimed at fulfilling unique 
synthetic goals such as optimizing yield, ease of final purification, avoidance of racemic mixtures 
or economical scalability. As such, our synthetic goals regarding 15d-PMJ2 were specifically 
aimed at utilizing a “one pot” synthetic approach, using mild conditions to preserve the activity of 
the cyclopentenone ring while simultaneously maximizing yield since the cost of starting material 
is prohibitive.    
  To fulfill our synthetic requirements and utilize a “one pot” reaction approach, a class of 
reagents known as uronium coupling reagents were chosen as the best synthetic candidate. Two 
popular coupling reagents utilized for this synthesis were O-(Benzotriazol-1-yl)-N,N,N’,N’-
tetramethyluronium hexafluorophosphate (HBTU) and O-(Benzotriazol-1-yl)- N,N,N’,N’-
tetramethyluronium tetrafluoroborate (TBTU). These coupling reagents were developed for their 
extremely efficient amide bond coupling and are now an industry standard for peptide synthesis. 
Coupling reactions using these reagents occur in as little as six minutes and when 1-
hydroxybenzotriazole (HOBt) is added, racemization can be reduced to insignificant levels [62]. 
Additionally, these reagents are also particularly useful in our case as by-products from the 
coupling reaction are soluble in aqueous solutions, allowing for separation by liquid-liquid 
extraction or HPLC. The coupling reaction begins by deprotonation of the carboxylic acid with 




by-product (Figure 3.2). Next, the activated ester is subjected to nucleophilic attack by the amino 
group of ethanolamine to give the final amidated product (Figure 3.2). The final ionic product, 
HOBt, which is formed from the uronium salt is aqueous soluble and thus can be readily separated 



















Figure 3.1: Optimization strategy for synthesizing 15d-PMJ2  
To maximize reaction yield and recovery, the conjugation of ethanolamide was optimized and 
carried out using heptadecanoic acid C17:0, linoleic acid C18:2, and arachidonic acid C20:4 to 
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Figure 3.2: Mechanism of amide bond coupling by uronium salt 
Amide bond coupling begins by deprotonating the carboxylic acid with base followed by formation 
of the activated ester and tetramethylurea. Lastly, the activated ester is attached at the amino group 













































3.2.1 Synthesis of heptadecanoyl-ethanolamide 
 A comprehensive study was carried out to determine the appropriate solvent conditions for 
dissolving the coupling reagent, HBTU, and heptadecanoic acid (HDA) within the same solution. 
The best solvent balance was found to be 88% dimethylformamide (DMF) and 12% 
dichloromethane. Changes in percentages of these solvents resulted in the precipitation of HBTU 
or HDA. To a solution containing 50 mg HDA, 1.1 molar equivalents HBTU, 2 molar equivalents 
of N,N-diisoproylethylamine (DIEA) followed by 2 molar equivalents ethanolamine were added. 
HBTU is not added in excess as it can react with double bonds and unprotected N groups. The 
contents were allowed to mix for 3 hours and then poured into a separatory funnel containing 50 
mL dichloromethane. A thick emulsion formed when diH2O was added, therefore, 3 extractions 
were performed with 20 mL brine solution followed by 3 extractions with diH2O.  The organic 
layer was collected and dried using 25 mg sodium sulfate, then filtered using 24/40 Whatman filter 
paper. The final solution was rotary evaporated under medium heat to yield a white solid. Residual 
dimethylformamide following rotary evaporation would require subsequent extractions using ethyl 
acetate followed by overnight vacuum distillation. This reaction was performed a total of three 
times with the average recovery yield of 75%.   
 Analytical verification of heptadecanoyl-ethanolamide was performed by 1H-NMR (Figure 
3.3). The peaks found at ~3.45 ppm and ~3.75 ppm corresponded to the successful addition of the 
ethanolamide group and comparison of integration values corresponding to these peaks with that 
of 0.9 ppm (terminal carbon corresponding to 3 protons) indicated a ~95% conversion. The 1.65 




3.2.2 Synthesis and optimization of linoleoyl-ethanolamide   
 The synthesis of linoleoyl-ethanolamide was attempted using the same procedure as 
heptadecanoyl-ethanolamide, however due to the high aqueous partition of DMF, contamination 
with this solvent occurred at higher frequency. This required additional extraction steps which 
drastically decreased product recovery. Any attempt to remove DMF using vacuum distillation 
under moderate heat resulted in complete oxidation of double bonds of linoleic acid. As such, we 
sought to remove DMF from the synthetic scheme by replacing the coupling reagent with one 
which possessed greater solvent flexibility. The uronium salt TBTU was found to be an appropriate 
alternative, with at least one group reporting moderate solubility in ethyl acetate [63]. Under our 
experimental conditions, however, TBTU was found to be soluble in acetonitrile, but not ethyl 
acetate. The majority of fatty acids and prostaglandins are readily soluble in acetonitrile (ACN) 
and as such, all following synthetic reactions were carried out using TBTU in 100% acetonitrile.    
 Linoleic acid, N’N-diisopropylethylamine and TBTU were dissolved in acetonitrile, which 
upon mixing, changed the solution from clear to faint pink to copper. This color transition is most 
likely the result of chelation of the activated carboxyl group. Once ethanolamine was added to the 
reaction mixture, the solution turned yellow and formed a white, shimmery precipitate. The crude 
product was then vacuum filtered, re-dissolved in 30mL DCM and extracted 3 times with diH2O. 
Rotary evaporation produced a faint yellow oil. Recovery from this method was reported to be 
greater than 100% and analysis of 1H-NMR spectra revealed a prominent peak at ~2.75 ppm. The 
impurity associated with this peak was determined to be tetramethylurea, which has been 
reportedly removed by using ether or heptanes as organic extraction solvents [64]. The subsequent 
reaction was performed identically but extracted with diethyl ether instead of DCM. Rotary 




showed 95% reaction yield with no presence of the previous impurity, tetramethylurea (Figure 
3.4).  
3.2.3 Synthesis and optimization of arachidonoyl-ethanolamide (AEA) 
 Preliminary synthesis of AEA using the same method to produce linoleoyl-ethanolamide 
was successful, however, slight oxidation of double bonds was apparent from analysis of 1H-NMR 
spectrum. The presence of four labile double bonds urged the use of inert atmosphere and as such, 
all following reactions were carried out under nitrogen gas using a Schlenk line apparatus in dark 
conditions. Unlike reaction solutions containing linoleic acid, solutions with arachidonic acid 
underwent no color changes upon addition of DIEA and only a white precipitate formed following 
the addition of ethanolamine. Work up was identical to that of linoleoyl-ethanolamide, with the 
exception that rotary evaporation was performed at low temperature to yield a clear oily product.  
 Analysis of 1H-NMR indicated a 99% reaction yield with all double bonds intact (Figure 
3.5A). Furthermore, mass spectral analysis of the product showed two major peaks at m/z 370 and 
386 which corresponded to sodium and potassium conjugated AEA, respectively (Figure 3.5B). 
To confirm the biological activity of synthesized AEA, murine tumorigenic JWF2 keratinocytes 
were treated with 5, 10, 15, 20 or 30 µM AEA and cell viability was measured by MTS assay 
(Figure 3.5C). Synthesized AEA decreased the cell viability by 43% at 20 µM and 92% at 30 µM. 
These values were found to be comparable with commercially available AEA, validating the 
cytotoxic activity of synthetic AEA in tumorigenic keratinocytes. These data demonstrate 






 3.2.4 Synthesis and verification of 15-deoxy-Δ12,14-prostamide J2  
  To synthesize 15-deoxy-Δ12,14-prostamide J2 (15d-PMJ2), the commercially available non-
ethanolamide J-series prostaglandin, 15 deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2), was used as the 
synthetic substrate (Figure 3.6A). Prior to conducting the synthesis, the precursor molecule, 15d-
PGJ2, was characterized by 
1H-NMR (Figure 3.6C). To a solution containing 10 mg 15d-PGJ2, 1.1 
molar equivalents TBTU, 2 molar equivalents of N,N-diisoproylethylamine (DIEA) followed by 
2 molar equivalents ethanolamine were added. The work-up of 15d-PMJ2 was carried out using 
the same method found to successfully produce AEA. Unfortunately, product recovery using this 
method was severely diminished to 15%. Extractions of the discarded aqueous phase with ethyl 
acetate recovered much of the lost product, however, oxidation of the double bonds was apparent 
from analysis.  Moving forward, diethyl ether was replaced with ethyl acetate as the primary 
extraction solvent during work-up. This change increased recovery, but the higher boiling 
temperature of ethyl acetate required greater heating during rotary evaporation which decreased 
double bond retention. In light of these findings, the use of high performance liquid 
chromatography (HPLC) was employed to purify 15d-PMJ2. The crude product was dissolved in 
1:1 H2O:ACN and run through a BioRad HPLC C18 prep column with a H2O/ACN solvent 
gradient. The retention time for 15d-PMJ2 was found to be 13.80 minutes at 71% ACN (Figure 
3.6B). The collected peak was then freeze dried over night to yield a clear oil.  
 Verification of 15d-PMJ2 was carried out by performing 
1H-NMR and mass spectrometry. 
1H-NMR spectra of 15d-PMJ2 was almost identical to the synthetic substrate (15d-PGJ2), but also 
reported proton peaks associated with the addition of the ethanolamide group (Figure 3.6C, D 
denoted with red letters). Analysis of 1H-NMR confirmed the retention of all double bonds and 




showed one major peak corresponding to the m/z of 382.2 which was determined to be sodium 
conjugated 15d-PMJ2 (data not shown). These data definitive demonstrate the first reported 





















Figure 3.3 Analytical verification of heptadecanoyl-ethanolamide by 1H-NMR.  
Spectra was acquired from a 400 MHz Bruker instrument with molecules dissolved in CDCl3. Peak 
































Figure 3.4 Analytical verification of linoleoyl-ethanolamide.  
Linoleoyl-ethanolamide was synthesized according to the procedure described above. 1H-NMR 
spectra was acquired from a 400 MHz Bruker instrument with molecules dissolved in CDCL3. 
Numbers on molecular structure indicate proton shifts in spectra. Peak integration was performed 
































Figure 3.5 Analytical and biological validation of arachidonoyl-ethanolamide  
Arachidonoyl-ethanolamide was synthesized according to the procedure described above. (A) 1H-
NMR Spectra was acquired from a 400 mHz Bruker instrument with molecules dissolved in d-
CDCL3. (B) Mass spectral verification of arachidonoyl-ethanolamide was performed on a 
MircoMass time-of-flight mass spectrometer by direct injection with molecules dissolved in MS-
grade ACN. (C) JWF2 tumorigenic keratinocytes were treated with 5 µM, 10 µM, 15 µM, 20 µM 
and 30 µM concentrations of synthesized AEA for 24 hours. Cell viability was evaluated by 
conducting MTS experiments. Data represent mean ± SEM of three independent experiments and 
are expressed as percent of untreated group. * P < 0.05, as compared to vehicle. 
















































































Figure 3.6 Synthesis and verification of 15 deoxy-Δ12,14-prostamide J2.  
(A) 15 deoxy-∆12,14 prostaglandin J2 was reacted with ethanolamine in the presence of 
diisopropylethylamine and the uronium coupling reagent TBTU. Reaction was conducted in 100% 
acetonitrile under nitrogen atmosphere. (B) HPLC chromatograph for 15d-PMJ2 . (C) H
1-NMR 
and structure of synthetic substrate 15 deoxy-∆12,14 prostaglandin J2  (15d-PGJ2). (D) H
1-NMR and 
structure of 15 deoxy-∆12,14 prostamide J2. Spectra was acquired from 400 MHz Bruker instrument 

































































































 Gaining insight into the mechanisms associated with COX-2 mediated AEA cytotoxicity 
is an important topic of interest. Hence, the goal of this study was to perform the first synthesis of 
the terminal COX-2 AEA metabolite, 15d-PMJ2. In order to accomplish this task, our approach 
employed the use of model compounds to develop the ideal synthetic conditions for the attachment 
of an ethanolamine group to a J-series prostaglandin, yielding the first J-series prostamide. To 
proceed with this approach, we explored chemical and solubility properties of various coupling 
reagents for amide bond formation. The use of diisopropylcarbodiimide (DIC) was explored as a 
potential coupling reagent in early synthetic schemes of linoleoyl-ethanolamide, but was quickly 
eliminated due to difficulty in work-up and low recovery. Uronium coupling reagents were found 
to be the best fit for our scenario due to their high yield and ease of removal. The solubility of 
HBTU was limited to DMF, which proved nearly impossible to remove, hence, TBTU was chosen 
due to its versatile solubility, particularly in acetonitrile.     
Model compounds such as linoleic acid and arachidonic acid provided valuable synthetic 
insight regarding acceptable work-up conditions for unstable molecules possessing double bonds. 
These compounds demonstrated physical changes upon oxidation which was useful in developing 
the best practices for handling unsaturated lipids during processes of transferring, pipetting, 
storage etc. These physical changes were noted as yellowing or browning of the solution color, 
increased viscosity of the product oil, or irreversible adhesion to glass surfaces. We found that the 
model compounds, linoleic and arachidonic acid do not possess quite the same partition 
coefficient, thus initial recovery of 15d-PMJ2 was low.  Preliminary synthesis using diethyl ether 
were found to be successful in working up linoleoyl-ethanolamide and AEA, but not 15d-PMJ2. 




chromatography (HPLC). Interestingly, 15d-PMJ2 was also found to considerably less stable than 
that of arachidonic acid or AEA. Indeed, our observations indicate that 15d-PMJ2 is significantly 
more susceptible to degradation by oxidation, which is most likely due to highly electrophilic 
nature of the cyclopentenone ring. Exceptional care should be used whenever handling or 
transferring 15d-PMJ2 in the presence of atmospheric oxygen.   
 The biological activity of AEA was confirmed in tumorigenic keratinocytes by means of 
cytotoxicity assay. Furthermore, cell death measured in keratinocytes treated with synthesized 
AEA was greater than that of commercially available AEA (data not shown). This may be 
attributed to the fact that synthetic AEA is recently produced whereas commercial AEA may be 
been stored for long periods of time, leading to slow degradation. To more extensively characterize 
the biological activity of synthesized AEA, future studies may include detecting its binding to 
















CHAPTER FOUR: EVALUATION OF THE ANTI-TUMOR ACTIVITY OF 15D-PMJ2 
IN VITRO AND IN VIVO 
 
4.1 ABSTRACT 
 Skin cancer including melanoma and non-melanoma skin cancer (NMSC) is the most 
prevalent form cancer in the US. Many malignancies including skin cancer overexpress the 
enzyme cyclooxygenase-2 (COX-2). The major role of COX-2 is to convert arachidonic acid to 
prostaglandins (PGs) including prostaglandin E2 (PGE2). PGE2 is known to promote cancer by 
activating anti-apoptotic signals and angiogenesis. In contrast, the COX-2 metabolite, 15-deoxy, 
Δ12,14prostaglandin J2 (15d-PGJ2) inhibits cancer cell survival by promoting apoptosis via 
mechanisms including oxidative- and endoplasmic reticulum (ER)-stress. We previously reported 
that the endocannabinoid, AEA, selectively induced apoptosis in tumorigenic NMSC cells and that 
this activity was dependent on the metabolic formation of J-series prostamides. As such, we set 
out to evaluate the anti-tumor activity of 15-deoxy-Δ12,14-prostamide J2 (15d-PMJ2) in vitro and in 
vivo. We began by evaluating the antineoplastic activity of PMD2, the upstream metabolite of 15d- 
PMJ2 and found that the D-series prostamide derivative exhibited greater cytotoxic and apoptotic 
properties in NMSC and melanoma cells compared to PGD2. Like PMD2, 15d-PMJ2 was found to 
induce cell death and apoptosis in both non-melanoma skin cancer and melanoma cell lines at 
considerably lower concentrations than 15d-PGJ2. To evaluate whether 15d-PMJ2 exhibits 
preferential toxicity and induction of apoptosis, tumorigenic and non-tumorigenic keratinocytes 
and melanocytes were assayed for viability and the cleavage of pro-apoptotic proteins caspase-3 
and PARP following 15d-PMJ2 treatment. We report a significant difference in cell death between 
tumorigenic and non-tumorigenic cell lines. Furthermore, 15d-PMJ2 was found to induce cleavage 




15d-PMJ2 against melanoma in vivo, B16F10 allograft tumors grown in C57/BL6 mice were dosed 
subcutaneously with 0.5 mg/kg 15d-PMJ2 for 5 days. Tumors treated with 15d-PMJ2 exhibited 
significantly reduced growth and mean weights compared to vehicle and untreated animals. 
TUNEL analysis of tumor tissues demonstrated significant levels of cell death in 15d-PMJ2-treated 
tumors compared to vehicle and untreated tumors. Taken together, these findings show that the 
endocannabinoid metabolite, 15d-PMJ2, possesses potent and selective activity against cancer cells 


















Skin cancer is the most common human neoplasm in America with one in every five  
individuals developing this malignancy in their lifetimes [3]. Skin cancer is comprised of two 
major subtypes including non-melanoma skin cancer (NMSC) and melanoma. NMSC consists of 
basal and squamous cell carcinoma and is less aggressive and metastatic compared to melanoma. 
The annual cost of treating all types of skin cancer is estimated to be a staggering $8.1 billion 
dollars annually [65]. Furthermore, studies indicate that the incidence of these cancers is on the 
rise primarily due to increased exposure to ultraviolet radiation. 
Currently, treatment for NMSC involves surgical excision, low-dose radiation, or 
application of chemotherapeutic agents including 5-fluorouracil and imiquimod. NMSCs most 
often occur on highly sun-exposed areas such as the face and ears. In some instances, surgical 
procedures may be disfiguring, leaving large scars or blemishes. The most common anti-neoplastic 
agent for the treatment of NMSC, 5-fluorouracil, acts principally by interrupting the synthesis of 
the nucleoside thymidine through inhibition of the enzyme thymidylate synthase. Adverse effects 
associated with this agent include skin inflammation when administered topically and 
myelosuppression when administered systemically. Imiquimod, a more recently developed 
immunomodulating agent, activates toll-like receptors (TLR7) within the immune system, 
resulting in the release of cytokines and the activation of the adaptive immune system. The 
culminating effect is the recruitment of natural killer (NK) cells, macrophages and lymphocytes 
which target the tumor for destruction. Side effects from imiquimod include skin damage, severe 
inflammation, and flu-like syndrome. While these agents provide effective treatment for the 
management of NMSC, the adverse effects generated from these agents arises from the lack NMSC 




Treatment of melanoma skin cancer is very distinct from NMSC. The inherent danger 
associated with melanoma is its highly aggressive and metastatic nature, making management 
clinically challenging. Primary melanoma tumors are surgically removed and if metastasis to other 
organs has occurred, immunotherapy and radiation therapy is initiated. Biological checkpoint 
inhibitors such as ipilimumab are a newer class of immunotherapeutic agents which block 
cytotoxic T-lymphocyte-associated protein 4 (CTLA4) thereby initiating T-lymphocyte-mediated 
tumor recognition and destruction of metastatic melanoma cells. These agents have increased 
survival rates of patients with unresectable melanoma, however the potentially fatal 
immunological adverse effects of check-point inhibitors coupled with the difficulty of predicting 
patient response limits their clinical use. As such, the need for novel chemotherapeutic agents to 
improve patient survival while causing fewer side effects is greater than ever.  
Apoptosis is a tightly regulated form of immune-tolerant programmed cell death which is 
characterized by the activation of distinct energy-dependent cellular pathways. Morphologically, 
hallmarks of apoptotic cells include the condensation of chromatin and the formation of distinct 
plasma membrane blebs known as apoptotic bodies. The initiation of apoptosis can by stimulated 
through three separate pathways including the intrinsic pathway, the extrinsic pathway, and the T-
cell-mediated granzyme pathway all of which converge onto activation of the major executioner 
protein, caspase-3. The intrinsic pathway involves permeabilization of the mitochondrial 
membrane, causing release of cytochrome c into the cytosol which then forms the apoptosome and 
subsequently activates caspase-3. In cancer, achieving apoptosis as a therapeutic outcome provides 
numerous advantages over necrotic-type cell death including decreased inflammatory response 
and reduced collateral non-tumor cell killing. Indeed, it is reported that in chemotherapy-treated 




mechanisms. As such, chemotherapeutic agents which demonstrate proficiency at selectively 
targeting tumor-cells for apoptotic cell death can ultimately provide therapeutic success with less 
incidence of adverse effects.  
Endocannabinoids are endogenously synthesized lipids that bind to and signal through 
cannabinoid receptors. These lipid messengers modulate neuronal signaling, inflammation, 
cardiovascular function and other physiological processes. In addition, endocannabinoids and their 
receptors are reported to be involved in both the development and elimination of cancer, indicating 
that the pathophysiological interaction between cancer and endocannabinoids requires further 
study [66-68]. Several reports suggest that the antitumor activity of AEA occurred through 
cannabinoid receptor-dependent and -independent mechanisms including the induction of 
endoplasmic reticulum (ER) stress [69-73].  
Our group previously reported that the endocannabinoid, AEA, caused selective induction 
of apoptosis and cell death in NMSC cells. Furthermore, recent data from our group identified a 
newly discovered J-series prostaglandin-ethanolamide (prostamide), 15-deoxy, Δ12,14-prostamide 
J2 (15d-PMJ2) [43;74]. Specifically, we found that AEA was metabolized by cyclooxygenase-2 
(COX-2) to prostaglandin-ethanolamide D2 [prostamide D2 (PMD2)] which was converted to the 
terminal product, 15d-PMJ2.  Previous studies by our group demonstrated that metabolism by 
COX-2 was needed for AEA cytotoxicity but that the cannabinoid receptors had little impact on 
its activity.  The prevention of AEA-mediated cell death by blocking 15d-PMJ2 production 
suggested that the anti-proliferative action of AEA was caused by 15d-PMJ2. Therefore, in the 
current study, we evaluated whether the novel prostamide, 15d-PMJ2, was an inducer of tumor cell 
death in vitro and in vivo. We also examined whether apoptotic effects of 15d-PMJ2 were 




assess the feasibility of utilizing 15d-PMJ2 as a potential selective anti-tumor agent against skin 







4.3.1 Upstream metabolic precursor of 15d-PMJ2, PMD2 induces apoptotic cell 
death in melanoma and non-melanoma skin cancer cells.  
The endocannabinoid, AEA, undergoes COX-2 mediated conversion to prostamides 
followed by metabolism to D-series prostamides by prostaglandin D synthase. Our group  
demonstrated that D-series prostamides are subsequently dehydrated to the terminal end-product, 
15d-PMJ2 [43]. To determine the anti-proliferative activity of the D-series prostanoids against skin 
cancer cells, JWF2 (non-melanoma skin cancer) and B16F10 (melanoma) cells were treated with 
increasing concentrations of PMD2 and PGD2 for 24 hours and cell viability was measured by 
MTS assay. JWF2 and B16F10 cells treated with 10 and 20 µM PMD2 displayed a significant 
reduction in cell survival (Figure 4.1A and B). Alternatively, PGD2 only decreased viability at the 
20 µM concentration, suggesting that PMD2 possesses greater cytotoxicity. To determine whether 
D-series prostanoids induce apoptotic cell death, JWF2 and B16F10 cells were treated with 10 or 
20 µM PMD2 or PGD2 for 24 hours and the cleavage of PARP was measured by Western blot 
analysis. At 20 µM, the presence of both PMD2 and PGD2 led to increased expression of cleaved 
PARP in both melanoma and non-melanoma skin cancer cells when compared to vehicle treated 
cells (Figure 1C and D). These results suggested that D-series prostanoids induce apoptotic cell 
death in skin cancer lines.  
4.3.2 15d-PMJ2 is a potent inducer of cell death in skin cancer cells.  
To evaluate the cytotoxic activity of 15d-PMJ2 in skin cancer cells, B16F10 melanoma 
cells, along with A431 and JWF2 squamous cell carcinoma cell lines were treated with increasing 




assay. 15d-PMJ2 caused a concentration dependent decrease in cell viability. The LC50 
(concentration of agent which causes death in 50% of the cells) value of 15d-PMJ2 was calculated 
and is determined to be 4.7 µM for A431 and 3.3 µM JWF2 cells (Figure 4A, C). In B16F10 
melanoma and patient derived primary melanoma cells, the LC50 values were calculated to be 3.3 
µM and 3.0 µM respectively (Figure 4B, D). 15-deoxy, Δ12,14 prostaglandin J2 (15d-PGJ2) is a 
molecule that is distinct, yet structurally related to 15d-PMJ2. 15d-PGJ2 is synthesized by COX-2 
from the substrate arachidonic acid rather than AEA. Because arachidonic acid-derived 15d-PGJ2 
induces tumor cell death [75], the cytotoxic activity of this molecule was compared to novel, 15d-
PMJ2. In non-melanoma skin cancer cells the LC50 values for 15d-PGJ2 were found to be greater 
than 20 µM for A431 and 11.4 µM for JWF2 (Figure 4A, C). In melanoma skin cancer cells, the 
LC50 values for this agent were calculated to be 15.5 µM and 10.5 µM in B16F10 and patient 
derived primary melanoma respectively (Figure 4B, D). Overall, 15d-PMJ2 and 15d-PGJ2 
exhibited cytotoxic properties in all skin cancer cell lines tested, however, 15d-PMJ2 was found to 
be 3- to 4-times more potent than 15d-PGJ2 (Figure 4E).  
4.3.3 15d-PMJ2 treatment elicits apoptotic cell death in skin cancer cells.  
J-series prostaglandins induce apoptosis in tumorigenic cell lines [76]. As such, we sought 
to test the mechanism of cell death associated with 15d-PMJ2 adminstration by measuring caspase-
3/7 activity. In JWF2 and A431 NMSC cells, exposure to 5 µM 15d-PMJ2 led to an approximate 
600 and 1000 fold increase in caspase-3/7 activity respectively, when compared to vehicle (Figure 
5). Furthermore, melanoma cell lines treated with 15d-PMJ2 exhibited 400- and 900- fold increase 
in caspase-3/7 activity respectively, when compared to vehicle (Figure 5). These data 




4.3.4  15d-PMJ2 demonstrates preferential cytotoxicity toward tumorigenic skin 
cells. 
To examine whether 15d-PMJ2 preferentially targets tumor cells, tumorigenic (A431, 
JWF2 and B16F10) and non-tumorigenic (HaCaT, C-50 and Melan-A) skin cells were treated with 
increasing concentrations of 15d-PMJ2 and viability was assessed by conducting MTS assays. 
Tumorigenic A431 keratinocytes were more susceptible to 15d-PMJ2 cytotoxicity as reflected by 
a 53% and 83% reduction in viability at 5 µM and 10 µM respectively, whereas a minimal 
reduction in viability (5% at 5 µM and 8% at 10 µM) was observed at the same concentration in 
HaCaT cells (Figure 4.4A). In tumorigenic JWF2 cells, 5 µM and 10 µM exposure to 15d-PMJ2 
led to a 77% and 99% reduction in viability, while in non-tumorigenic C-50 cells, a 21% and 64% 
reduction in cell viability respectively, was observed (Figure 4.4B). Similarly, B16F10 melanoma 
cells were preferentially targeted by 15d-PMJ2 with a 64% and 90% decrease in viability at 5 µM 
and 10 µM respectively, compared to Melan-A cells whose survival increased at 5µM and 
decreased by 24% at the 10 µM concentration (Figure 4.4C). At the 5 µM concentration, the fold 
difference in cytotoxicity between tumorigenic and non-tumorigenic cell lines was found to be 2 
(A431), 39 (JWF2) and 3.6 (B16F10), providing strong evidence for induction of selective toxicity 
by 15d-PMJ2 (Figure 4.4).  
4.3.5 15d-PMJ2 selectively induces apoptosis in tumorigenic skin cells.  
To investigate whether 15d-PMJ2 (5 µM) selectively induces apoptosis, caspase-3 and 
PARP cleavage was examined by Western blot in tumorigenic and non-tumorigenic cell lines. Our 
results showed that 15d-PMJ2 markedly increased caspase-3 and PARP cleavage in A431 cells 
while caspase-3 and PARP cleavage was not detected in HaCaT cells (Figure 4.5A). A prominent 




while Melan-A cells treated under identical conditions showed no significant caspase or PARP 
cleavage (Figure 4.5B). Furthermore, arachidonic acid derived 15d-PGJ2, exhibited significantly 
less PARP and caspase-3 cleavage in tumorigenic A431 and B16F10 compared to its ethanolamide 
conjugated counterpart thereby supporting our previous observation that 15d-PMJ2 exhibits greater 
potency than 15d-PGJ2. Collectively, these data indicate that 15d-PMJ2 preferentially causes 
apoptotic cell death in tumorigenic compared to non-tumorigenic skin cells. 
4.3.6 Solid tumors treated with 15d-PMJ2 exhibit retarded growth, decreased mass, 
and increased tumor cell death.  
To evaluate the anti-tumor effect of 15d-PMJ2 in vivo, C57BL/6 mice allografted with 
B16F10 tumors were dosed with 0.5 mg/kg of 15d-PMJ2, PBS or tumors were left untreated for 5 
consecutive days. Animals dosed with 0.5 mg/kg displayed significantly reduced tumor size 
compared to vehicle and untreated. Tumor volumes measured on day 3 were found to be 14.4 mm3, 
57.0 mm3 and 46.9 mm3 for 0.5 mg/kg, vehicle and untreated respectively. Differences in tumor 
volumes reached significance by day 5, with the 0.5 mg/kg dosed group possessing a mean tumor 
volume of 20.0 mm3 compared to 115.6 and 85.3 mm3 in vehicle and untreated tumors (Figure 
4.6A). In addition, the mass of resected tumors was found to be dramatically decreased in the 0.5 
mg/kg group compared to the control groups (figure 4.6B).   
To address the question of whether the anti-tumor effect of 15d-PMJ2 was caused by 
inducing tumor cell death, terminal deoxynucleotidyl transferase dUTP nick-end labeling 
(TUNEL) positive cells were measured in resected tumors. The TUNEL assay employs a 
fluorescent tagged nucleotide to detect double stranded DNA breaks which are indicative of late 
stage apoptosis and other forms of cell death. Tumors dosed with 0.5 mg/kg 15d-PMJ2 displayed 




groups (Figure 4.7). These data coupled with our previous findings demonstrate the anti-tumor 






















Figure 4.1: PMD2 and PGD2 induce potent apoptotic cell death in melanoma and non-
melanoma skin cancer cells.  
(A) JWF2 keratinocytes and (B) B16F10 melanoma cells were treated with 2.5 µM, 5.0 µM, 10 
µM and 20 µM concentrations of PMD2 or PGD2 for 24 hours. Cell viability was evaluated by 
MTS assay according to the manufacturer’s instructions. (C) JWF2 and (D) B16F10 cells were 
treated with 10 µM and 20 µM PMD2 or PGD2 for 24 hours. The cleavage of PARP was assayed 
by Western blot analysis. Data and images represent mean ± SEM of three independent 
experiments and are expressed as percent of untreated group. Data were analyzed using one way 
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Figure 4.2: 15d-PMJ2 displays potent cytotoxicity in skin cancer cells.  
(A) JWF2 non-melanoma skin cancer cells, (B) B16F10 melanoma cells, (C) A431 non-melanoma 
skin cancer cells and (D) patient derived primary melanoma cells were treated with 1 µM – 20 µM 
concentrations of 15d-PMJ2 of 15d-PGJ2 for 24 hours. Cell viability was measured by MTS assay 
and is expressed as percentage of untreated control cells. (E) Tabulated LC50 values calculated for 
15d-PMJ2 and 15d-PGJ2. Data represent mean ± SEM of three independent experiments. *P < 



























































































































































Figure 4.3: 15d-PMJ2 induces apoptotic cell death in skin cancer cell lines.  
JWF2, A431, B16F10, or patient primary melanoma cells were treated with 5 µM 15d-PMJ2 or 
vehicle for 24 hours and caspase-3/7 activity was measured by Caspase-Glo. Values are 




















































































































Figure 4.4: 15d-PMJ2 demonstrates preferential cytotoxicity in tumorigenic skin cancer cells. 
(A) A431 and HaCaT keratinocytes treated with 1 µM - 20 µM 15d-PMJ2 or vehicle for 12 hours. 
(B) JWF2 and C-50 cells were treated with 1 µM - 20 µM 15d-PMJ2 or vehicle for 24 hours. (C) 
B16F10 melanoma and Melan-A melanocytes were treated with 1 µM -20 µM 15d-PMJ2 or vehicle 
for 24 hours. Cell viability was evaluated by conducting MTS assay and is expressed as percentage 
of untreated cells. Data represent mean ± SEM of three independent experiments. * P < 0.05, when 



























































































































Figure 4.5: 15d-PMJ2 selectively induces apoptosis in tumorigenic skin cells.  
(A) A431 and HaCaT cells were treated with vehicle, 5µM 15d-PGJ2 or 15d-PMJ2 for 6 and 8 
hours. (B) B16F10 and Melan-A cells were treated with vehicle, 5µM 15d-PGJ2 or 15d-PMJ2 for 
16 and 20 hours. The cleavage of PARP and caspase-3 was assayed by Western blot analysis. Fold 
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Figure 4.6: Treatment with 15d-PMJ2 inhibits solid melanoma tumor growth in vivo.  
(A) B16F10 allografted tumors were subcutaneously treated with vehicle (0.1% DMSO in PBS) 
or 0.5 mg/kg 15d-PMJ2 and the tumor volume was measured daily. (B) Tumors were resected 24 
hours following the final treatment, blotted dry, and weighed. * P < 0.05, when comparing 15d-



























































































Figure 4.7:  15d-PMJ2 induces tumor cell death in vivo.  
Paraffin embedded tumor sections were analyzed by TUNEL assay for cell death. TUNEL positive 
cells (green fluorescence) and nuclear DAPI staining (blue fluorescence) were detected by 
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4.5  DISCUSSION  
With the prevalence of skin cancer on the rise due to increased sun and UV light exposure, 
the need for novel and effective anti-neoplastic agents is greater than ever. As such, this study was 
first to biologically characterize the novel AEA metabolite, 15-deoxy-prostamide J2, and evaluate 
its anti-cancer activity in vitro and in vivo. In the present report, we determined that 15d-PMJ2 
induced apoptotic tumor cell death in both non-melanoma and melanoma skin cancer cells. 
Furthermore, our results showed that 15d-PMJ2 demonstrated significantly higher potency 
compared to the non-ethanolamide J-series prostaglandin 15d-PGJ2. Tumorigenic keratinocytes 
and melanocytes treated with exogenous PMD2 (which is the upstream metabolic precursor of 15d-
PMJ2) produced similar levels of cell death and PARP cleavage as 15d-PMJ2 suggesting that PMD2 
elicits its activity through metabolism to 15d-PMJ2 (Figure 4.1). Of clinical importance, 15d-PMJ2 
exhibited preferential cytotoxicity and induction of apoptosis in tumorigenic vs non-tumorigenic 
cells suggesting this agent will produce fewer adverse effects. Lastly, we determined that 15d-
PMJ2 induces cell death in solid tumors using a B16F10 allograft model. Taken together, these 
results support our hypothesis that 15d-PMJ2 is a potent and preferential inducer of cell death in 
skin cancer.  
15d-PMJ2 exhibited striking cytotoxicity against skin cancer cell lines, primary patient 
melanoma cells, as well as xenograft melanoma tumors suggesting a potential role for this agent 
in cancer chemotherapeutic regimens.  The IC50 values of 15d-PMJ2 treated tumorigenic cells were 
in the low micromolar range. Our results also demonstrated that 15d-PMJ2 displayed anti-tumor 
activity in vivo, with a 0.5 mg/kg dose producing a substantial reduction in tumor growth and 
weight by promoting tumor cell death (Figures 4.6-7). In support of our findings, other research 




death in leukemia, melanoma and colorectal carcinoma xenografts [77;78]. Another group showed 
that cholangiocarcinoma xenograft tumor growth was also decreased with AEA treatment, a 
precursor of 15d-PMJ2 [79;80].  Furthermore, a non-degradable analog of AEA, methanandamide 
(met-F-AEA) prevented lung xenograft tumor development [81].  In light of the fact that our group 
has shown that the cytotoxic effect of AEA is primarily mediated by 15d-PMJ2 [43], these findings 
support the assertion that 15d-PMJ2 most likely prevents tumor growth in various animal models 
and may potentially curb tumor growth in humans. 
Prostaglandins are formed as a result of the metabolism of AA by COX-2 whereas 
prostaglandin-ethanolamides (prostamides) are produced from the metabolism of AEA by COX-
2. However, little is known about the biological differences between these structurally-related 
molecules. Kozak et. al. found that prostamides possessed significantly longer plasma half-lives 
and were less subject to metabolic degradation than prostaglandins [82].  Matias et al, established 
that prostamides of the E, F, and D-series possessed unique pharmacological and biological 
activity compared to their prostaglandin counterparts as they did not bind to traditional 
prostaglandin receptors [45]. As a result of these findings, considerable effort is now focused on 
identifying cellular receptors of prostamide ligands [83;84]. We determined that the activity of 
15d-PMJ2, was similar to 15d-PGJ2, but that 15d-PMJ2 was a considerably more potent inducer of 
cell death and apoptosis. We report that IC50 the values calculated for 15d-PGJ2 were consistently 
3-5 times higher than that of 15d-PMJ2, indicating the superior potency of 15d-PMJ2. Furthermore, 
15d-PGJ2 only demonstrated the capability to induce apoptotic cleavage of caspase-3 and PARP 
in NMSC but not melanoma cells, suggesting 15d-PGJ2 may not be suitable for as an anti-
melanoma agent. In agreement with these findings, structure-activity relationship studies carried 




acid of Δ12-PGJ3 significantly increased J-series prostaglandin potency against leukemia [85]. Like 
J-series prostaglandins, upstream metabolites PMD2 and PGD2, showed differences in killing 
capacity of tumor cells with potency found to be higher in the prostamide variation. This evidence 
strongly suggests that 15d-PMJ2 may interact with distinct cellular targets or possess robust 
stability compared to 15d-PGJ2 providing a potential explanation for the differences in activity 
shown here. 
Targeting cancers using agents which display selective tumor cell cytotoxicity results in 
fewer dose-limiting adverse effects and better overall patient quality of life. This study reports that 
15d-PMJ2 possesses preferential toxicity toward both tumorigenic melanocytes and keratinocytes. 
We demonstrated previously that the endocannabinoid AEA selectively induced apoptosis in 
tumorigenic keratinocytes through the formation of J-series prostamides [43]. Furthermore, 
prostaglandins of the D- and J-series induced apoptosis in tumorigenic but not non-tumorigenic 
cell lines [86]. Indeed, 15d-PGJ2 caused cell death in tumorigenic T-cells while possessing limited 
toxicity in non-tumor T-cells and other normal cell types suggesting differential effects based on 
drug concentrations and cell type characteristics (16) [87]. At 5 µM, 15d-PMJ2 was found to induce 
greater than 50% cell death in tumorigenic keratinocytes and melanocytes whereas no or only 
partial cell death was reported in non-tumorigenic cells (Figure 4.4). Of perhaps greater 
importance, 15d-PMJ2 promoted significant cleavage of pro-apoptotic caspase-3 and PARP in 
tumorigenic but not non-tumorigenic skin cells (Figure 4.5). Selective tumor cell death through 
induction of apoptosis provides numerous clinical advantages such as decreased immunogenic 
response and reduced inflammation. Overall, these findings agree with our earlier reports that AEA 




this or other studies utilizing J-series prostaglandins or cannabinoids [78;79], 15d-PMJ2 may be a 



















CHAPTER FIVE: THE ANTI-TUMOR ACTIVITY OF 15D-PMJ2 IS CONFERED 
THROUGH ER-STRESS MEDIATED CALCIUM CHANNEL ACTIVATION. 
 
5.1 ABSTRACT 
 Our lab previously demonstrated that the endocannabinoid, AEA, induces apoptotic cell 
death in an ER- and oxidative stress-dependent manner without engagement of the cannabinoid 
receptors. We also determined that the cytotoxic activity of AEA was primarily mediated by its 
metabolic product, 15d-PMJ2. Therefore, we sought to elucidate the mechanism of 15d-PMJ2 
mediated apoptotic cell death. The data show that ER-stress markers, phospho-PERK and 
CHOP10 were required for 15d-PMJ2 mediated apoptosis and were also selectively upregulated in 
tumor but not non-tumor skin cancer cells. We also observed increased phosphor-PERK and 
CHOP10 in allografted melanoma tumors in vivo.  In cultured skin cancer cells, 15d-PMJ2 also 
increased intracellular Ca2+ whose elevated levels were important for initiation of ER-stress 
mediated cell death.  Although 15d-PMJ2 significantly increase oxidative stress, this process was 
not required for tumor cell death. 15d-PMJ2 contains and electrophilic α,β-unsaturated carbonyl 
group on its cyclopentenone ring that readily adducts to free sulfhydryls of cellular proteins. As 
such, we examined the role of this moiety in cell death by synthesizing a neutral analog of 15d-
PMJ2 that lacked the double bond. Our results showed that neutral-15d-PMJ2 did not cause cell 
death at doses at which 15d-PMJ2 was lethal. We also report that 15d-PMJ2 induced oxidative 
stress, ER stress and Ca2+ mobilization was also regulated by the electrophilic double bond. Based 
on these findings, the ability of 15d-PMJ2 to selectively induce ER stress mediated tumor cell 
apoptosis indicates that this agent may be a valuable addition to current chemotherapeutic regimes 





The ER is a major site for folding of secreted, transmembrane and organelle localized 
proteins. The ER provides an ideal environment for protein due to the presence of chaperones that 
catalyze oxidative-, calcium-, disulfide-mediated bond formation. Under some circumstances, the 
number of proteins which require folding assistance will inundate the protein folding machinery 
of the ER and elicit what is known as the unfolded protein response (UPR) [46;47]. In attempt to 
restore homeostasis, HSP70/GRP78 (BiP), a multifunctional ER-chaperone, localizes to the 
unfolded proteins within the ER lumen and releases three distinct UPR sensors, to which BiP was 
previously attached. When BiP dissociates from the ER-membrane localized sensors, PERK, 
ATF6, and IRE1α, the ER-stress signaling cascade is activated [48]. In tumor cells, the decision 
to resolve the unfolded insult or undergo apoptosis is dependent on the intensity and duration of 
the ER stress signal. During short bouts of ER-stress, IRE1, PERK and ATF6 activate signal 
transduction pathways that culminate in increased peptide folding and protein degradation 
responses with the goal of restoring ER homeostasis and promoting survival [49]. However, during 
times of prolonged ER-stress signaling, the UPR sensors upregulate the expression of pro-
apoptotic transcriptional factor C/EBP homologous protein (CHOP10)/growth arrest and DNA 
damage inducible 153 (GADD153), leading to cell death [89].  
Recently, cellular death inducer protein-1 (CDIP1) was found to be a key regulator of ER-
stress mediated apoptosis in vitro and in vivo [50]. Indeed, CDIP1 was found to act as signal 
transducer during the ER stress response through its complexation with the integral ER membrane 
protein, B-cell receptor-associated protein 31 (BAP31). BAP31 is an important participant in ER-
mitochondria induced death as it has been reported that the cleavage of BAP31 into p20-BAP31 
initiates apoptotic signals from the ER by increasing IP3 receptor mediated Ca




to mitochondrial Ca2+ uptake and subsequent apoptosis [90]. Furthermore, complex formation 
between CDIP1 and p20-BAP31 has been demonstrated to induce caspase-8 activation and 
sequestration of pro-survival B-cell lymphoma-2 (Bcl-2) proteins [50]. As such, BAP31 leads to 
transduction of signals between the ER and mitochondria in ER-stress mediated cell death.  
 The ER and mitochondria serve as the major Ca2+ reservoirs within the cell due to the 
essential role Ca2+ plays in maintaining a favorable environment for protein folding and cellular 
metabolism. In the ER, Ca2+ gradients needed for oxidative protein folding are established by the 
sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) while excess calcium is pumped out of the 
ER by the ryanodine (RyR) and inositol 1,4,5-triphosphate receptors (IP3R).  Similarly, Ca
2+ that 
is required for cellular metabolism and ATP production is pumped into the outer mitochondrial 
membrane through the voltage-dependent anion-selective channel (VDAC) and into the 
mitochondrial lumen through the mitochondrial calcium uniporter (MCU). Slow discharge of Ca2+ 
from the mitochondria occurs through the VDAC, while large bursts of Ca2+ can exit during 
apoptosis through the mitochondrial permeability transition pore (mPTP). In addition, Ca2+ flux 
between these two organelles occurs at specialized ER-mitochondrial interfaces known as 
mitochondrial-associated ER membranes (MAMs) [91]. Indeed, the ER-IP3R and mitochondrial-
VDACs located within the MAM are anchored to one another through a tethering protein known 
as cytosolic chaperone glucose-regulated protein 75 (GRP75) [92]. Under normal circumstances, 
IP3R-mediated Ca
2+ transmission from the ER to the mitochondria supports ATP production and 
is under control of the ER chaperone Sigma-1 receptor (Sig-1R) [93]. During prolonged ER stress, 
sustained Ca2+ release may occur through interactions of IP3R with numerous ER stress protein 
effectors including ER-membrane associated oxidoreductase-α (ERO1α), p20-BAP31, and Sig1R 




including  generation of ROS and sensitization of cyclophilin D, which contributes to the opening 
of the mPTP [58].  Stimulation of the mPTP results in the bolus release of cytochrome c, a crucial 
event in formation of the apoptosome, that causes irreversible induction of the intrinsic apoptotic 
pathway. Thus, Ca2+ transfer between the ER and mitochondria plays a vital role in regulating ER-
stress mediated apoptotic cell death.  
 Numerous lines of evidence demonstrate that ER stress facilitates ROS production and 
reciprocally, ROS activates ER stress induction [95;96]. Under normal conditions, oxidative 
protein folding occurring within the ER carried out by protein disulfide isomerase (PDI) and 
ERO1α, is believed to contribute approximately 25% of ROS generated by the cell [97]. In fact, 
the misfolding of proteins under stress conditions is reported to perturb ER redox status and 
generate ROS by influencing ERO1α and PDI activity leading to decreased levels of reduced 
glutathione [98]. In addition, the depletion of Ca2+ from the ER has also been reported to induce 
ROS by causing mitochondrial dysfunction, decreased neutralization of ROS and stimulating NO 
synthesis [99;100]. Hence an intimate relationship between protein folding, ROS, and Ca2+ flux 
exists. 
 Our group previously demonstrated that the upstream metabolite of 15d-PMJ2, AEA, 
induced ER- and oxidative-stress which was required for apoptosis [88]. As such, we hypothesize 
that the anti-tumor activity of 15d-PMJ2 is reliant on these mechanisms, however, the role of these 
pathways on cell death is unclear. Preliminary data from our group also suggested that treatment 
with AEA increased intracellular Ca2+ levels and based on this finding, we investigated the 
importance of Ca2+ signaling on cell death induced by 15d-PMJ2. Furthermore, it was reported that 
J-series prostaglandins confer induction of ROS and cell death through an electrophilic 




evaluate the significance of this moiety in 15d-PMJ2, a neutral analog (neutral-5d-PMJ2) was 






















5.3.1 15d-PMJ2 induces ER-stress in vitro and in vivo.  
The ER stress pathway has been identified as a chemotherapeutic target that can confer 
selective toxicity [102]. Previous work conducted by our group demonstrated that AEA induced 
ER-stress in tumorigenic keratinocytes and that the cytotoxicity of AEA was mediated by its 
metabolic product 15d-PMJ2. To determine the effect of 15d-PMJ2 on ER-stress production in 
tumorigenic skin cells, we measured the expression of the early-phase ER-stress marker, PERK, 
and the late ER-stress/apoptotic marker, CHOP10 by Western blot analysis. During ER stress, 
PERK becomes activated by undergoing homodimerization and autophosphorylation. 
Furthermore, insurmountable or prolonged ER stress increases the expression of pro-apoptotic 
CHOP10. As such, PERK phosphorylation and CHOP10 expression were examined as indicators 
of ER stress. ER stress was selectively activated by 15d-PMJ2 in tumorigenic but not non-
tumorigenic skin cells as demonstrated by the notable increase in phospho-PERK levels in 
tumorigenic A431 and B16F10 cells (Figure 5.1A, B).  Moreover, expression of the cytotoxic ER 
stress protein, CHOP10, was also significantly increased in tumorigenic but not non-tumorigenic 
cells (Figure 5.1A, B). Arachidonic acid derived 15d-PGJ2 was also found to upregulate both ER 
stress proteins selectively in the tumorigenic cell lines although 15d-PMJ2 elicited greater 
induction of cytotoxic CHOP10 (Figure 5.1A, B). To investigate the whether 15d-PMJ2 generates 
ER-stress in vivo, phospho-PERK and CHOP10 levels were examined in solid tumors treated with 
0.5 mg/kg 15d-PMJ2.  15d-PMJ2 promoted ER stress as demonstrated by significant increases both 
phospho-PERK and CHOP10 content in the tumors (Figure 5.1C, D). As anticipated, none of the 





5.3.2 Oxidative stress is generated by 15d-PMJ2 in skin cancer cells.  
In addition to the ability of J-series prostanoids to promote tumor cell death through 
propagation of ER-stress, many groups have proposed that redox alterations caused by these 
biomolecules are a possible mechanism of apoptosis [76]. Furthermore, 15d-PGJ2 has been shown 
to induce intracellular ROS and oxidative stress by decreasing glutathione levels, inhibiting 
mitochondrial complex 1 and generating reactive aldehydes. To evaluate if 15d-PMJ2 induces 
oxidative stress, tumorigenic JWF2 and B16F10 cells were treated with 5 µM 15d-PMJ2 and 
oxidative stress was examined by measuring fluorescence of the redox sensitive probe, DCFDA. 
15d-PMJ2 increased DCFDA fluorescence by roughly 380% in JWF and 450% in B16F10 
compared to vehicle treated cells (Figure 5.2A, B). In accordance with our previous results, 
oxidative stress from 15d-PMJ2 was also found to be significantly higher than that of 15d-PGJ2.  
5.3.3 ER-but not oxidative-stress is required for 15d-PMJ2-mediated apoptotic cell 
death.  
Some groups have reported that oxidative stress generated by the arachidonic acid derived 
15d-PGJ2 is required for cell death, while our group has reported that both ER- and oxidative stress 
were required for AEA-mediated cell death [43;76]. To test if the generation of ER- and/or 
oxidative-stress, is required for 15d-PMJ2-mediated apoptosis the use of an antioxidant and two 
ER-stress inhibitors were employed. ER-stress was blocked by using the pharmacological ER-
stress inhibitors, salubrinal and 4-phenylbutrate (4-PBA), while oxidative stress was inhibited by 
using trolox. Salubrinal elicits its activity by selectively inhibiting PP1/GADD34 thereby 
preventing the dephosphorylation of phospho-eIF2α. Dephosphorylation of eIF2α is required to 
allow protein translation to resume. In constast, PBA inhibits ER-stress by acting as a chemical 




findings that ER-stress is a key regulator of AEA mediated apoptosis, both salubrinal and to a 
greater extent, 4-PBA significantly prevented caspase-3/7 activity in A431, B16F10 and JWF2 
skin cancer cells treated with 15d-PMJ2 (Figure 5.3A-C). Next we examined the role of oxidative 
stress in 15d-PMJ2 induced death using trolox a water-soluble vitamin E analog that exhibits anti-
oxidant activity by neutralizing free radicals. In JWF2 and B16F10 cells pretreated with trolox, a 
significant reduction in DCFDA fluorescence occured. However, trolox did not prevent caspase-
3/7 activity or tumor cell death (Figure 5.4A-F). These results indicate that ER stress but not 
oxidative stress is required for 15d-PMJ2 cytotoxicity.   
5.3.4 Induction of cell death by PMD2 and PGD2 is mediated by ER-stress but not 
DP or PPAR gamma receptors.  
D-series prostaglandins spontaneously undergo non-enzymatic conversion to J-series 
prostaglandins by dehydration. Moreover, this non-enzymatic reaction form an equilibrium in 
which J-series prostaglandins can also rehydrate to produce D-series prostaglandins [19]. As such, 
we investigated the antineoplastic mechanism of upstream metabolite, PMD2. To test whether ER-
stress was required for PMD2-mediated cell death in JWF2 and B16F10 tumor cells, ER-stress was 
blocked by 30-minute pretreatment with salubrinal and GSK2606414 (a small molecule inhibitor) 
followed by treatment with 20 µM PMD2 or PGD2 (the arachidonic acid counterpart). 
GSK2606414 prevents the propagation of ER-stress by inhibiting the phosphorylation of eIF2α by 
PERK [105]. In JWF2 and B16F10 cells, both salubrinal and GSK2606414 significantly reduced 
cell death induced by both PMD2 and PGD2 confirming the role of ER-stress in D-series prostanoid 
activity (Figure 5.5A, B).   
PGD2 is a well-known agonist of D type prostanoid receptors [subtype 1 (DP1) and 2 




endogenous ligand of peroxisome proliferator activated receptor gamma (PPARγ). The DP1 and 
DP2 receptors are G-protein coupled receptors while PPARγ is a nuclear receptor. DP1, a Gαs 
coupled receptor, and DP2 a Gi coupled receptor, are known to regulate the anti-inflammatory 
effect of PGD2, however the effect of these receptors on cancer cell progression remains widely 
unknown [106-108]. 15d-PGJ2 is thought to covalently bind to a free cysteine residue within the 
binding pocket of PPARγ, causing nuclear localization,  heterodimerization with the retinoic acid 
receptor (RXR) and expression of target genes [36]. In the context of cancer, there is increasing 
evidence that PPARγ signaling may be important in regulating processes including inflammation, 
proliferation, differentiation, and apoptosis [109-111]. As such, we examined the requirement for 
DP1, DP2 and PPARγ receptors in PGD2 and PMD2-mediated cell death. To investigate the role 
of DP1 and DP2 receptors on the anti-tumorigenic properties of PMD2 and PGD2, the use of 
selective receptor antagonists BWA868C (BW, DP1), BAYU3405 (BAY, DP2) were employed 
[26;76].   JWF2 cells were pretreated with BW (1µM) and BAY (10µM) followed by treatment 
with PMD2 or PGD2. Pretreatment with DP receptor antagonists did not reverse the cytotoxic 
effects of either PMD2 or PGD2 suggesting that DP receptors are not required for the anti-cancer 
activity (Figure 5.5C). Likewise, to determine the role of PPARγ on the cytotoxic properties of 
PGD2 and PMD2, JWF2 cells were pretreated with 5 or 20 µM of the irreversible receptor 
antagonist, GW9662 [112]. Similarly, pretreatment with GW9662 caused no change in the 
cytotoxic behavior of PMD2 or PGD2 suggesting that the anti-cancer activity of these molecules is 






5.3.5 ER-stress mediated calcium channel activation is essential for 15d-PMJ2 
activity.   
It has been established that ER Ca2+ concentration modulates cellular sensitivity to 
apoptosis [113]. Furthermore, Ca2+ efflux during stress from the ER lumen into cytosol or 
mitochondria has been demonstrated to facilitate the apoptosis [57]. As such, we sought to 
determine if ER-stress mediated Ca2+ flux is involved in 15d-PMJ2 cytotoxicity. To characterize 
the influence of 15d-PMJ2 on intracellular Ca
2+ flux, JWF2 and B16F10 cells were treated with 
15d-PMJ2 and intracellular Ca
2+ was measured. 15d-PMJ2 caused a significant increase in 
intracellular Ca2+ compared to control (Figure 5.6A, B). To evaluate whether the 15d-PMJ2-
mediated increase in intracellular Ca2+ was due to the activation of IP3, a selective IP3 receptor 
inhibitor, 2-aminoethoxydiphenyl borate (2-APB), and a non-selective calcium channel inhibitor, 
ruthenium red (RR), were employed. Pretreatment with both 2-APB and RR caused a nearly 
complete reversal of the 15d-PMJ2-mediated increase in intracellular Ca
2+ suggesting that the 
intracellular calcium is originated from IP3 ER stores (Figure 5.6C, D). It has been reported that 
ER-stress associated pathway proteins such as the PERK and BAP31 mediate pro-apoptotic ER 
Ca2+ efflux [114;115]. To determine if induction of ER-stress by 15d-PMJ2 was responsible for 
the increase in intracellular Ca2+, ER-stress was blocked with salubrinal or GSK2606414 followed 
by treatment with 15d-PMJ2. NMSC and melanoma skin cancer cells pretreated with salubrinal 
and GSK2606414 displayed significantly lower intracellular Ca2+ levels compared to cells treated 
with 15d-PMJ2 (Figure 5.6E, F). This data provides evidence that ER stress activation is necessary 
for increasing intracellular Ca2+ content. To determine whether increased intracellular Ca2+ was 
needed for cell death, the viability of NMSC and melanoma skin cancer cells was measured 




15d-PMJ2-mediated cytotoxicity in JWF2 cells (Figure 5.6G). In addition, 2-APB and RR reversed 
15d-PMJ2 cytotoxicity by 60-to-70% in B16F10 cells (Figure 5.6H).   
5.3.6 Initiation of apoptotic cell death by 15d-PMJ2 is mediated by the 
cyclopentenone double bond.  
Thus far, we have demonstrated that 15d-PMJ2 treated tumor cells undergo apoptosis 
involving an ER-stress-calcium channel-dependent mechanism. However, we have yet to examine 
the molecular mechanisms responsible for this activity. Indeed, this information would provide 
valuable insight toward synthesizing more potent derivatives. As such, our group undertook the 
task of identify the specific molecular pharmacophore associated with 15d-PMJ2 mediated activity.  
     J-series prostaglandins, are known to covalently modify cysteine residue present on 
proteins through interaction with the cyclopentenone moiety  [101]. We hypothesized that through 
this mechanism, 15d-PMJ2 may confer its anti-tumor activity by activating the ER stress pathway. 
Hence, the molecular mechanism by which 15d-PMJ2 elicits anti-tumor activity was examined by 
investigating the role of the double bond contained within the cyclopentenone ring of the molecule. 
To address this question, a neutral analog of 15d-PMJ2 (neutral-15d-PMJ2; Figure 5.7A) lacking 
the reactive double bond was synthesized (Materials and Methods section). To determine the role 
of this reactive double bond on cytotoxicity, A431, JWF2, B16F10 and patient-derived melanoma 
cells were treated with increasing concentrations of neutral-15d-PMJ2 and compared to 15d-PMJ2. 
Neutral-15d-PMJ2 did not decrease cell viability in A431, B16F10 or patient-derived melanoma 
cells, but decreased survival in JWF2 cells at 20 µM. In contrast, concentrations of 15d-PMJ2 
greater than 1 µM significantly decreased viability in each cell line (Figure 5.7B-E). Next, we 
sought to determine whether neutral-15d-PMJ2 induces apoptosis in skin cancer cells by measuring 




significant increase in caspase-3/7 activity compared to vehicle treated cells. This was in stark 
comparison to 15d-PMJ2 which increased caspase-3/7 activity by 501%, 372%, and 768% in A431, 
JWF2, and B16F10 cells, respectively.    
5.3.7 ER stress, oxidative stress and calcium mobilization are mediated by the 
cyclopentenone double bond of 15d-PMJ2. 
It has been demonstrated that the double bond structure in arachidonic acid derived 15d-
PGJ2 promotes oxidative stress through covalent interactions with cysteine-containing proteins in 
an ordered fashion [116]. The role of the cyclopentenone double bond in ER stress however, has 
not been investigated. To determine the role of the reactive double bond in the generation of ER-
and oxidative-stress, JWF2 and B16F10 skin cancer cells were probed for ER-and oxidative-stress 
markers following treatment with 5 µM neutral-15d-PMJ2 or 15d-PMJ2. 15d-PMJ2 and neutral 
15d-PMJ2 caused a significant increase in DCFDA fluorescence compared to vehicle cells, 
however 15d-PMJ2 was more potent than the neutral derivative (Figure 5.8A, B). In addition, the 
phosphorylation of PERK and the expression of CHOP10 were significantly blunted in neutral-
15d-PMJ2 compared to 15d-PMJ2 cells, demonstrating the requirement for the reactive double 
bond in the generation of ER-stress (Figure 5.8C, D). Lastly, we assessed calcium flux in the 
presence of neutral-15d-PMJ2 and found that accumulation of intracellular Ca
2+ was also 
dependent on the double bond (Figure 5.8E, F).  
  5.3.8   15d-PMJ2 induces ER-stress associated CDIP1-BAP31 signaling. 
To further characterize the mechanism of 15d-PMJ2-mediated ER stress-apoptosis, 
additional modulators of this cytotoxic pathway were examined. CDIP1 has been identified as a 




presence of ER stress, CDIP1 expression is upregulated and the protein dimerizes with 
constitutively expressed BAP31. BAP31-CDIP complexes are necessary for BAX oligomerization 
and apoptosis via caspase-8 [50].  In addition, caspase-4 is known to be selectively cleaved as a 
consequence of ER stress initiated apoptosis [118]. 15d-PMJ2, but not neutral 15d-PMJ2 
significantly upregulated the expression of CDIP1 and cleavage of caspase-4 (Figure 5.9A). 
Furthermore, CDIP1 was observed to co-localize with Bap31 whereas the neutral molecule failed 
to promote co-localization (Figure 5.9B). Moreover, the cleaved form of caspase 8 was selectively 
induced by 15d-PMJ2 rather than its neutral analog. These results provide the first evidence that 
the cyclopentenone double bond is required for expression of CDIP1 and subsequent propagation 

















 Figure 5.1: 15d-PMJ2 induces ER-stress in vitro and in vivo.  
(A) A431 and HaCaT cells were treated with vehicle, 5µM 15d-PGJ2 or 5 µM15d-PMJ2 for 2 
(upper panel) and 4 hours (lower panel). (B) B16F10 and Melan-A cells were treated with 
vehicle, 5µM 15d-PGJ2 or 15d-PMJ2 for 6 (upper panel) and 8 (lower panel) hours. The 
phosphorylation of PERK and expression of CHOP10 was assayed by Western blot analysis. 
Fold increase was determined via densitometry with ImageJ software. (C) CHOP10, total-PERK, 
and phospho-PERK expression was evaluated in B16F10 allografted tumors by conducting 
immunohistochemical analysis. (D) Histograms show the mean optical density of CHOP10, 
phospho-PERK, and total PERK analyzed using ImageJ software. Data are presented as mean ± 
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Figure 5.2: 15d-PMJ2 induces oxidative stress.  
(A) JWF2 and (B) B16F10 cells were treated with 5 µM 15d-PMJ2, 15d-PGJ2 or vehicle for 2 
hours. Oxidative stress was measured using flow cytometry with CM-H2DCFDA reagent. 
Fluorescence was measured as a percent increase from untreated control. Data are presented as 
mean ± SEM and represent three independent experiments. * P < 0.05, when comparing 15d-





























































































































Figure 5.3: ER-stress is required for 15d-PMJ2–mediated apoptosis. 
(A) A431, (B) B16F10 and (C) JWF2 cells were pretreated with salubrinal or 4-PBA for 30 
minutes followed by treatment with vehicle or 5 µM 15d-PMJ2 for 6 (A, C) or 16 (B) hours. 
Caspase-3/7 activity was measured and is represented as percent of untreated. Data are presented 
as mean ± SEM and represent three independent experiments. * P < 0.05, when comparing 



































+ - - - + - 
+ + - - - + 

























































Figure 5.4: Oxidative stress is not required for 15d-PMJ2–mediated activity. 
(A) JWF2 and (B) B16F10 cells were pretreated with 0.5 mM trolox for 30 minutes followed by 
treatment with vehicle or 5 µM 15d-PMJ2 for 2 hours. Oxidative stress was measured by CM-
H2DCFDA fluorescence by flow cytometry. DCF fluorescence is reported as percent of 
untreated. (C) JWF2 and (D) B16F10 cells were pretreated with 0.5 mM trolox for 30 minutes 
followed by treatment with vehicle or 5 µM 15d-PMJ2 for 2 hours. Caspase-3/7 activity was 
measure used Caspase-Glo according to the manufacturer’s protocol. Trolox pretreated (E) JWF2 
and (F) B16F10 was treated with 15d-PMJ2 and cell viability was measured by MTS assay. Data 
are presented as mean ± SEM and represent three independent experiments.* P < 0.05, when 































































































































































































































































Figure 5.5: Cytotoxic activity conferred by PMD2 is ER-stress dependent, but DP-and 
PPARγ receptor independent.  
 JWF2 cells were pretreated with (A) selective DP1 and DP2 receptor antagonists, BW and BAY 
for 1 hour or (B) the irreversible PPARγ antagonist GW9662 for 2 hours followed by treatment 
with PMD2 and PGD2 for 24 hours. (C) JWF2 or (D) B16F10 cells were pretreated with ER-
stress inhibitors salubrinal and GSK2606414 for 30 minutes followed by treatment with PMD2 
and PGD2 for 24 hours. Cell viability was determined by MTS assay. Data are presented as mean 
± SEM and represent three independent experiments.* P < 0.05, when comparing samples to 






























































































































































































































































Figure 5.6: Activation of Ca2+ channels by 15d-PMJ2 is ER-stress mediated and required 
for cell death. 
(Left side) JWF2 and (Right side) B16F10 cells were pretreated with calcium channel blockers 
ruthenium red, 2-APB (C, D) for 1 hour or ER-stress inhibitors salibrunal, GSK2606414 (E, F) 
for 30 minutes followed by treatment with 5 µM 15d-PMJ2 or 10 µM thapsigargin for 1 hour. 
Intracellular Ca2+ levels were measured Fluor-4 NW assay. (G) JWF2 and (H) B16F10 cells 
were pretreated with ruthenium red (0.25 or 2.5 µM) or 2-APB (10 or 20 µM) for 1 hour 
followed by treatment with 15d-PMJ2. Cell viability was determined by MTS assay. Data are 
presented as mean ± SEM and represent three independent experiments.* P < 0.05, when 
comparing samples to vehicle-treated cells and # P < 0.05, when comparing samples to 15d-
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Figure 5.7: The cytotoxic and apoptotic effects of 15d-PMJ2 are mediated by the α,β-
unsaturated electrophilic double bond. 
(A) To determine the role of the cyclopentenone moiety in 15d-PMJ2-mediated anti-tumor 
activity, neutral-15d-PMJ2 was synthesized using the same synthetic approach described in 
chapter 3. (B) A431, (C) patient-derived melanoma, (D) JWF2, and (E) B16F10 cells were 
treated with 1, 2.5, 5, 10, or 20 µM concentrations of 15d-PMJ2 or neutral-15d-PMJ2 for 24 
hours and cell viability was measured by MTS assay. (F) JWF2, (G) B16F10, and (H) patient- 
derived melanoma cells were treated with 15d-PMJ2 for 6 hours. Caspase-3/7 activity was 
measured and is represented as percent of untreated. Data are presented as mean ± SEM and 
represent three independent experiments.  * P < 0.05, when comparing samples to vehicle-
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Figure 5.8: The induction of oxidative and ER-stress as well as calcium channel activation 
by 15d-PMJ2 are mediated by the electrophilic double bond. 
(A) JWF2 and (B) B16F10 cells were treated with 5 µM 15d-PMJ2, neutral-15d-PMJ2 or vehicle 
for 2 hours. Oxidative stress was measured using flow cytometry with CM-H2DCFDA reagent. 
Fluorescence was measured as a percent increase from untreated control. (C) A431 cells were 
treated with vehicle, 5µM 15d-PMJ2 or neutral-15d-PMJ2 for 6 (upper panel) and 8 (lower panel) 
hours. The phosphorylation of PERK and expression of CHOP10 was assayed by Western blot 
analysis. Fold increase was determined via densitometry with ImageJ software. (D) JWF2 and 
(E) B16F10 cells treated with vehicle, 5 µM 15d-PMJ2 or neutral-15d-PMJ2 for 1 hour. 
Intracellular Ca2+ levels were measured Fluor-4 NW assay. Data are presented as mean ± SEM 
and represent three independent experiments.  * P < 0.05, when comparing to 15d-PMJ2-treated 

























































































































































































































Figure 5.10: 15d-PMJ2 induces CDIP1-BAP31 signaling.  
(A) A431 cells were treated with vehicle, 5 µM 15d-PMJ2 or neutral-15d-PMJ2 for 6 hour. 
Expression levels of CDIP1 and cleavage of caspase-4 and caspase-8 was assayed by Western 
blot analysis. Fold increase was determined via densitometry with ImageJ software. (B) A431 
cells were treated with vehicle, 5 µM 15d-PMJ2 or neutral-15d-PMJ2 for 6 hour. Colocalization 
of CDIP1 (red fluorescence) and BAP31 (green fluorescence) was detected by confocal 
microscopy. Histogram shows quantification of intensity of CDIP1 and BAP31 fluorescence. 
Data were analyzed using ANOVA followed by Tukey multiple comparison test. Data are 
represented as mean ± SEM of three independent experiments. * P < 0.05, when comparing 
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 The goal of the present report was to gain insight into the molecular mechanisms 
underlying the apoptotic activity of the novel prostamide 15d-PMJ2.  In the previous chapter, we 
found that 15d-PMJ2 selectively induced cell death in tumorigenic but not non-tumorigenic skin 
cancer lines. Consistent with these findings, 15d-PMJ2 was also found to be a selective inducer of 
ER-stress in malignant skin cancer cells and this pathway was determined to be necessary for 15d-
PMJ2-mediated tumor cell death. Immunohistochemical analysis of tumor sample treated with 
15d-PMJ2 confirmed that ER-stress was also upregulated in vivo. Conversely, oxidative stress was 
heightened in 15d-PMJ2 treated cells, but this pathway was not required for cell death. 15d-PMJ2 
treatment in melanoma and NMSC cells significantly increased intracellular Ca2+ levels and these 
increased Ca2+ were necessary for cell death. In addition, activation of the ER-stress pathway was 
required to activate increased intracellular Ca2+ levels. Moreover, the cyclopentenone double bond 
in 15d-PMJ2 was critical for anti-tumor activity and the generation of ER-and oxidative stress. 
These results uncover mechanisms by which 15d-PMJ2 selectively induces tumor cell death and 
may possibly help determine phenotypes associated with tumor susceptibility for targeted therapy 
with agents such as 15d- PMJ2 and those possessing a similar mechanisms of action. 
 ER stress plays a key role in initiating apoptosis and agents that target this pathway can 
inhibit proliferation and induce death selectively in cancer cells. ER stress is heightened in cancer 
cells as a result of the increased protein folding demand that is needed to drive uncontrolled cell 
proliferation [49].  In addition, hypoxic conditions within most tumors impairs ATP production 
leading to an accumulation of unfolded proteins [49]. As such, agents that increase ER stress cause 
the cytotoxic threshold to be reached more readily in tumor cells than in non-tumor cells whose 




activated in tumor cells and that this pathway was required for 15d-PMJ2 and PMD2 mediated cell 
death.  ER-stress was also found to be upregulated in tumors of animals treated with 15d-PMJ2. In 
alignment with these results, others reported that arachidonic acid derived J-series prostaglandins 
induced cytotoxic ER stress in tumor cell lines although the selectivity of ER-stress induction in 
tumor cells was not examined [119]. Indeed, antineoplastic agents including bortezomib are being 
utilized clinically to modulate the ER-stress pathway as a therapeutic strategy suggesting that 15d-
PMJ2 may be a useful therapeutic through this mechanism [60].  
More recently, induction of ER-stress has been linked to increased expression of damage 
associated molecular patterns (DAMPs) and has also been demonstrated to play a role in the 
induction of immunogenic cell death (ICD). ICD is associated with an anti-tumor immune 
response mediated through dendritic cell activation and subsequent cytotoxic T-cell recruitment. 
Clinical used agents such as bortezomib, doxorubicin and oxaliplatin are known ICD inducers and 
are thought to exert additional anti-tumor activity through this mechanism [120].  Hence, agents 
such as 15d-PMJ2 which promote cytotoxic ER stress may also induce ICD and provide an added 
benefit for treating cancers in which ER stress levels can be exploited.  
 Oxidative stress can be defined as the imbalance between production of ROS and redox 
buffering anti-oxidants. Altered redox status and increased oxidative stress is a hallmark of cancer 
cells due to increased cellular metabolism and proliferation. Similar to ER-stress, promotion of 
oxidative stress can overload cellular redox capacity causing damage to DNA, proteins and lipids, 
thereby inducing apoptosis. In this dissertation, we report that 15d-PMJ2 potently induced the 
generation of oxidative stress in tumorigenic skin cancer cells, but that this phenomenon was not 
required for 15d-PMJ2-mediated apoptosis. Other cyclopentenone prostaglandins including 15d-




found to be required for 15d-PGJ2 activity [76;121]. In virtually all of these reports, the primary 
anti-oxidant used to prevent 15d-PGJ2-mediated activity was the thiol-containing compound, N-
acetylcysteine (NAC). Since cyclopentenone prostaglandins are hypothesized to exert activity by 
electrophilic Michael addition to thiol containing residues, an interaction between cyclopentenone 
prostaglandins and NAC would result in neutralization of the prostaglandin, instead of NAC-
mediated increases in GSH generation. Indeed, induction of cell death, ER-stress, autophagy, and 
heme oxygenase-1 (HO-1) by 15d-PGJ2 were found to be ameliorated with NAC but not other 
non-thiol anti-oxidants such as trolox and TEMPOL [119]. As such, we utilized the non-thiol, 
vitamin E analog trolox which we found to significantly decrease 15d-PMJ2-mediated oxidative 
stress, but not apoptosis or cell death. Moreover, oxidative stress has been shown to originate from 
mechanisms associated with ER-stress including elevated ERO1α activity and increased ER to 
mitochondrial Ca2+ flux [98;122]. This evidence suggests that the role of oxidative stress may be 
peripheral in nature or perhaps occurring through ER-stress related mechanisms, but nonetheless, 
are most likely not responsible for the cytotoxic activity of 15d-PMJ2.     
 Our group and others have proposed that D-series prostanoids can exert cytotoxic behavior 
through dehydration to J-series prostanoids [123]. We report that antagonism of DP-and PPARγ 
receptors had no effect on D-series prostanoid-mediated cell death. While PPARγ receptors are 
known to play a regulatory role cancer cell proliferation, other groups have shown that 15d-PGJ2 
exhibits activity independent of PPARγ [87;124;125]. Likewise, DP1- and DP2-receptor signaling 
has been reported in numerous cancer types including colon, gastic and ovarian [126-128]. 
Activation of these receptors produced a variety of receptor-dependent effects on tumor cells 
including decreased growth and angiogenesis [126;129]. As mentioned previously however, 




DP2 receptors [45]. Our data demonstrated that employing selective DP1 and DP2 receptor 
antagonists did not alter the cytotoxic capacity of either PGD2 or PMD2, supporting our hypothesis 
that conversion to cyclopentenone J-series prostanoids is a metabolic requirement for activity.       
 It is well established that fluctuations in intracellular Ca2+ can regulate important cellular 
processes including hormone secretion, cellular metabolism, and induction of signal transduction 
cascades. Moreover, Ca2+ also plays a pivotal role in cell division and conversely, cell death [53]. 
During the process of cell death, elevations in cytosolic Ca2+ levels participate in apoptosis through 
three distinct mechanisms, the activation of pro-apoptotic Ca2+- dependent proteases known as 
calpains, alteration in membrane structure by Ca2+-dependent phospholipid scramblases and 
opening of the mPTP due to mitochondrial Ca2+ overload [113]. In the current study, we report 
that 15d-PMJ2 treatments increased intracellular Ca
2+ levels and that these changes were required 
for cell death. Moreover, we report that 15d-PMJ2 also increased mitochondrial Ca
2+ (in future 
directions) perhaps implicated the mitochondria as the Ca2+-mediated apoptotic initiator of 15d-
PMJ2. Similar to our results, the Lin group reported that the arachidonic acid derived J-series 
prostaglandin, 15d-PGJ2, also dramatically increased Ca
2+ levels and that treatment with the Ca2+ 
sequestering agent, BAPTA, significantly reduced induction of pro-apoptotic proteins, death 
receptor-5 (DR-5) and CHOP10 [130]. Our results implicate IP3R as the most probable source of 
ER Ca2+ since 2-APB, an IP3R-specific inhibitor exhibited greater efficacy in decreasing Ca
2+ 
transit and cell death compared to the non-selective Ca2+ channel blocker, ruthenium red (RR). 
Curiously, differential rescue using Ca2+ channel blockers was observed in NMSC compared to 
melanoma cell suggesting that basal tumor cell levels of ER Ca2+ may dictate sensitivity to 15d-
PMJ2-mediated death. Indeed, the notion that ER Ca
2+ concentration modulates apoptotic 




involved in decreasing basal ER Ca2+ levels [113]. Additionally, we found that PERK-specific ER-
stress inhibitors significantly reversed Ca2+ changes suggesting that the effect of 15d-PMJ2 on Ca
2+ 
channel activation is PERK mediated. These results are consistent with our previous data that 
inhibition of the PERK pathway with salibrunal and GSK2606414 reversed 15d-PMJ2, PMD2 and 
AEA-mediated cell death [43]. As such, we hypothesize that 15d-PMJ2-mediated Ca
2+ channel 
activation is through the PERK pathway.  Although the specific ER-stress effector regulating 
homeostatic Ca2+ changes is not known, we report that 15d-PMJ2 increased BAP31 activation 
which is a PERK regulated protein and a known inducer of IP3R activity. Therefore we postulate 
that BAP31 may be the key transducer in PERK-mediated Ca2+ outflow.  
 15d-PMJ2 contains and electrophilic α,β-unsaturated carbonyl group on its cyclopentenone 
ring that readily reacts with thiol of cellular proteins [27]. The same electrophilic double bond is 
present in all cyclopentenone prostaglandins including the J- and A-series prostaglandins and 
prostamides. Generation of oxidative stress by arachidonic acid-derived 15d-PGJ2 has been 
attributed to interactions with anti-oxidants including glutathione and thioredoxin reductase 
[27;101]. These covalent interactions neutralize the anti-oxidants thereby allowing unchecked 
oxidant activity. However, it was unclear whether the cyclopentenone double bond also regulated 
ER-stress as disulfide bond formation plays a critical role in oxidative protein folding. To address 
this question our group synthesized a neutral-PMJ2 analog using the same approach described in 
chapter 3. Elimination of the reactive group in 15d-PMJ2 prevented apoptotic cell death in NMSC, 
melanoma and patient derived melanoma. Moreover, induction of oxidative/ ER-stress and 
increased intracellular Ca2+ was also prevented, thereby identifying the double bond as a critical 
moiety for activity of 15d-PMJ2. Studies are currently underway by our group to identify ER-stress 




 In the present study, we investigated the molecular mechanism of 15d-PMJ2, finding that 
this novel prostamide exerts its anti-tumor activity through the generation of ER, but not oxidative 
stress. Activation of ER-stress was also found to mediate increases in intracellular Ca2+ levels, 
which were also required to induce apoptosis. In agreement with previous work conducted with 
15d-PGJ2, elimination of the electrophilic double bond abolished the activity of 15d-PMJ2 





















































































CHAPTER SIX: GENERAL DISCUSSION AND SUMMARY 
 Non-melanoma and melanoma skin cancers represent a substantial cost to the United States 
health care system as the combined cost of treatment for these conditions is estimated to be 8.1 
billion dollars annually [3]. Chemotherapeutic treatments for NMSC involve the administration of 
5-fluorouricil and imquimod, which are effective but cause serious side effects. Melanoma, on the 
other hand is associated with significant mortality compared to NMSC and is treated with radiation 
and immunotherapy. The main objective of this dissertation project was to investigate the potential 
of 15d-PMJ2 as a novel therapeutic for the treatment of skin cancers, to provide a clinical 
alternative with less dose-limiting side-effects. This project was also focused on elucidating the 
mechanisms responsible for 15d-PMJ2-mediated apoptosis, thereby shedding light on tumor 
phenotypes associated with drug susceptibility.   
The first step in achieving our objective was to perform the first chemical synthesis and 
purification of 15d-PMJ2. Our general synthetic approach was to react a carboxyl-possessing J-
series prostaglandin with ethanolamine and an amide coupling reagent in the presence of N’N-
diisopropylethylamine to yield the J-series prostaglandin-ethanolamine. In order to determine the 
most appropriate solvents and optimize ideal synthetic conditions, we employed the use of fatty 
acid model compounds. Heptadecanoyl-ethanolamide was the first compound successfully 
synthesized using this method with the coupling reagent, HBTU. During the synthesis of the 
second model compound, linoleoyl-ethanolamide, HBTU was found to be an inappropriate 
coupling reagent due to its limited solubility. As such, we substituted HBTU with TBTU, which 
was found to be readily soluble in acetonitrile. The synthesis of arachidonoyl-ethanolamide offered 
unique challenges due to the four unsaturated double bonds but was structurally similar to the J-




under low light conditions. The synthesis of 15d-PMJ2 was performed by reacting 15d-PGJ2 with 
TBTU in the presence of ethanolamine and N’N-diisopropylethylamine, with purification being 
conducted on HPLC. Verification of molecule structures were performed by proton nuclear 
magnetic spectroscopy (1H-NMR) and electro-spray ionization mass spectrometry (ESI-MS).        
Our data provided the first pre-clinical characterization of 15d-PMJ2 which had superior 
cytotoxic activity compared to the synthetic substrate 15d-PGJ2. Unlike the endocannabinoid 
AEA, which required COX-2 to elicit its anti-tumor activity, we found that the cytotoxicity of 15d-
PMJ2, a downstream metabolite of AEA, was independent of this enzyme, demonstrating induction 
of apoptosis in NMSC and melanoma regardless of COX-2 expression. Moreover, selective 
toxicity of 15d-PMJ2 was found when comparing tumor vs. non-tumor cells from both murine and 
human origin, demonstrating pre-clinical consistency. In vivo peritumoral treatment of melanoma 
tumors with 15d-PMJ2 significantly retarded tumor growth and induced tumor cell death. 
Moreover, overt systemic toxicity was not observed during this study suggesting that the selective 
properties of 15d-PMJ2 may also apply to in vivo systems.  
Our group previously reported that AEA induced tumor cell apoptosis through mechanisms 
involving the induction of ER- and oxidative-stress [88]. Our similar yet distinct findings report 
that 15d-PMJ2-mediated toxicity was ER- but not oxidative stress dependent.  We also report that 
the generation of ER-stress was also observed in vivo. The requirement for oxidative stress to 
induce AEA-mediated death may be a result of other cyclooxygenase or lipoxagenase associated 
metabolites, a peroxidated variation of one of these bioactive lipids, or activation of their respective 
receptors. Treatment of cancer cells with AEA and 15d-PGJ2 produced a notable decrease in the 
redox buffering protein glutathione [88]. In addition to buffering free radicals, glutathione is also 




induce ER-stress [131]. The fact that J-series prostaglandins have been shown to localize to the 
ER may indicate that the effect of glutathione depletion on the generation of ROS and ER-stress 
is dependent on the sub-cellular locality [132]. Nevertheless, our data demonstrated that the non-
thiol containing anti-oxidant trolox reduced oxidative stress but not cell death, suggesting that 
oxidative-stress is dependent on the generation of ER-stress or is a parallel phenomenon.  
In our system, Ca2+ homeostasis was found to be a key regulator of 15d-PMJ2-mediated 
cell death. Previous reports indicate that related molecules, AEA and 15d-PGJ2, had the propensity 
to increase intracellular Ca2+ and some studies reported that this mechanism regulated apoptosis 
[130;133]. We found that increased cytosolic Ca2+ was required for cell death and was dependent 
on PERK-mediated ER-stress. We hypothesize that this effect is IP3-receptor mediated as selective 
antagonism of this channel provided greatest reversal of both Ca2+ flux and cell death. As such, 
further studies are required to determine whether cytosolic players such as calpain or the 
mitochondria are the major contributors during initiation of apoptosis. 
Lastly, this project sought to investigate the structural pharmacophore responsible for J-
series prostamide activity. Building on previous reports that J-series prostanoids confer activity 
through a reactive double bond within the cyclopentenone ring, we used the synthetic approach 
described in chapter 3 to produce the first J-series prostamide lacking this double bond. Our data 
definitively showed that this moiety was required for virtually all aspects of 15d-PMJ2-mediated 
activity. These data provide a valuable structure-activity relationship between the novel molecule, 
15d-PMJ2, and its mechanism, the selective generation ER-stress. These insights may ultimately 
help in developing novel and potent cyclopentenone/prostaglandin derivatives to combat cancers 






This dissertation provided strong evidence that generation of ER-stress was the most likely 
mechanism tumor-cell selective toxicity exhibited by 15d-PMJ2. In order to answer this question 
more definitively, protein folding abnormalities occurring within the ER of tumor cells should be 
mimicked to non-tumor cells, demonstrating the specific ER conditions required for 15d-PMJ2 
activity. This would provide valuable insights regarding potential off-target toxicities observed 
during administration. Our results demonstrated that 15d-PMJ2 dramatically increased intracellular 
Ca2+ levels, however the ultimate fate and consequence of this phenomena is still unknown.  
Increases in mitochondrial calcium are known to contribute to apoptotic cascade induction by 
resulting in cytochrome c release [57]. To investigate this role we examined whether 15d-PMJ2-
mediated increased intracellular Ca2+ was coinciding with increased mitochondrial Ca2+ levels. 
B16F10 and JWF2 cells treated for 4 hours with 15d-PMJ2 and 15d-PGJ2 displayed significant 
elevations in Rhod-2 fluorescence, a charged calcium probe which accumulates in the 
mitochondria (Figure 6.1). These data suggest that ER-mediated increased intracellular Ca2+ is 
most likely transiting to the mitochondria and contributing to initiation of apoptosis. To examine 
whether the cyclopentenone double bond was required for increased mitochondrial Ca2+, B16F10 
and JWF2 cells treated with neutral-15d-PMJ2 and 15d-PMJ2 for 4 hours were assayed for 
mitochondrial calcium using a Rhod-2 mitochondrial Ca2+ probe. Similarly to results regarding 
intracellular Ca2+, loss of the reactive double bond significantly decreased the level of 
mitochondria Ca2+ further demonstrating the importance of this moiety in 15d-PMJ2 efficacy 
(Figure 6.1).  
We demonstrated that 15d-PMJ2 decreased in vivo tumors using an immune-competent 




compromised models (such as patient-derived xenograft), which would shed light on both, the 
agents’ effect on patient derived tumors and the anti-tumor immunogenicity of 15d-PMJ2. Finally, 
formulating 15d-PMJ2 into a topical solution would enable the execution of a UV-induced skin 
cancer study, providing evidence that 15d-PMJ2 is effective against naturally occurring skin 

















Figure 6.1: Mitochondrial Ca2+ levels are induced by 15d-PMJ2 and is mediated by the 
electrophilic double bond. (A) JWF2 and (B) B16F10 cells treated with vehicle, 15d-PMJ2, or 
15d-PGJ2 for 4 hours. (C) JWF2 and (D) B16F10 cells treated with vehicle, 15d-PMJ2, or 
Neutral-15d-PMJ2 for 4 hours. Mitochondrial Ca
2+ levels were measured using Rhod-2. Data are 
presented as mean ± SEM and represent three independent experiments.* P < 0.05, when 
comparing samples to vehicle-treated cells and # P < 0.05, when comparing samples to 15d-
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